Introduction {#s1}
============

One of the most popular methods utilized to reduce gene expression in cells is RNA interference (RNAi). RNAi has been used in several studies to identify genes critical for the survival of human cancer cell lines ([@bib14]; [@bib26]; [@bib27]; [@bib46]; [@bib70]). During RNAi, gene expression is inhibited by small interfering (si)RNAs, small hairpin (sh)RNAs or micro (mi)RNAs. miRNAs are generated as primary transcripts in the nucleus where they undergo processing to pre-miRNAs by the Drosha-DGCR8 complex before being exported to the cytosol by exportin 5 ([@bib25]; [@bib38]). Once in the cytosol, pre-miRNAs and shRNAs are cleaved by Dicer, a type III RNase that functions in complex with TRBP, generating 21--23 nucleotide long fragments of double-stranded RNA (dsRNA) that have two nucleotide 3\' overhangs ([@bib74]). DsRNA fragments or chemically synthesized double-stranded siRNAs are loaded into the RNA-induced silencing complex (RISC) as single-stranded RNAs (the guide RNA) ([@bib63]). A near-perfect complementarity between the guide strand of the si/miRNA and the target mRNA sequence results in cleavage of the mRNA ([@bib55]). Incomplete complementarity results in inhibition of protein translation and contributes to mRNA degradation ([@bib24]). mRNA targeting is mostly determined by the seed sequence, positions 2-7/8 of the guide strand, which is fully complementary to the seed match in the 3\'UTR of targeted mRNAs. Similar to miRNAs, although not fully explored, siRNAs and shRNAs also target multiple mRNAs besides the mRNAs they were designed to silence---a phenomenon commonly referred to as off-target effect (OTE)---that is generally sought to be avoided ([@bib6]; [@bib30]; [@bib39]).

The death receptor CD95 (Fas/APO-1) mediates induction of apoptosis when bound by its cognate ligand CD95L, most prominently in the context of the immune system ([@bib37]). However, more recently, it has become apparent that the CD95/CD95L system has multiple tumor-promoting activities ([@bib51]). CD95 signaling promotes cell growth ([@bib12]), increases motility and invasiveness of cancer cells ([@bib3]; [@bib36]), and promotes cancer stemness ([@bib9]; [@bib16]; [@bib56]). In fact, we reported tumors barely grew *in vivo* when the CD95 gene was deleted ([@bib12]; [@bib26]). Therefore, it appeared consistent that multiple shRNAs and siRNAs targeting either CD95 or CD95L slowed down cancer cell growth ([@bib12]) and engaged a distinct form of cell death characterized by the activation of multiple cell death pathways ([@bib26]). This unique form of cell death cannot be inhibited by conventional cell death or signaling pathway inhibitors or by knockdown of any single gene in the human genome ([@bib26]); it preferentially affects transformed cells ([@bib26]) including cancer stem cells ([@bib9]). Here, we report that loading of CD95 and CD95L-derived sequences (si/shRNAs targeting CD95 or CD95L) into the RISC elicits a distinct form of cell death that results from the targeting of multiple survival genes in a unique form of OTE.

Results {#s2}
=======

si/shRNAs kill cells in the absence of the targeted site {#s2-1}
--------------------------------------------------------

More than 80% of multiple-tested shRNAs or siRNAs designed to target either CD95 or CD95L were toxic to multiple cancer cells ([@bib26]). We have now extended this analysis to Dicer substrate 27mer DsiRNAs designed to target CD95L ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, \[[@bib34]\]). All five DsiRNAs displayed toxicity when introduced into HeyA8 cells at 5 nM ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) reinforcing our previous observation that the majority of CD95 and CD95L targeting si/shRNAs are toxic to cancer cells. We also analyzed a data set of a genome-wide analysis of 216 cells infected with a pooled library of the TRC shRNAs ([@bib14]). Most of the shRNAs we have tested were found to be depleted in the infected cell lines included in this study. The following shRNAs were found to be depleted in the listed percentage of the 216 cell lines tested: shL4 (99.5%), shL1 (96.8%), shR6 (88.9%), shR7 (75%), shR3 (71.8%), shL2 (67.1%), shR5 (38.4%), shL5 (26.4%), and shR8 (21.3%) ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Consistent with our data, shL1 and shR6 were found to be two of the most toxic shRNAs. Again in this independent analysis, the majority of tested shRNAs (67%) targeting either CD95 or CD95L killed more than half of all tested cancer cell lines.

Interestingly, a more recent RNAi screen did not report toxicity after expressing shRNAs against CD95 or CD95L ([@bib46]). The authors of this study used a second-generation shRNA platform based on a miR-30 backbone. To determine the source of the discrepancy in the data, we generated miR-30-based Tet-inducible versions of some of our most toxic shRNAs (shL1, shL3, shL4, shR5, shR6, and shR7, [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}) and found none of them to be highly toxic to HeyA8 cells ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). To determine their knockdown efficiency, we induced their expression in cells carrying sensor plasmids in which the fluorophore Venus was linked to either the CD95L or CD95 open reading frame (ORF). Expression of most of these miR-30-based shRNAs also did not efficiently silence Venus expression ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). In contrast, two of our most toxic shRNAs shL3 and shR6 when expressed in the Tet-inducible pTIP vector not only killed HeyA8 cells, but also very efficiently suppressed Venus fluorescence in cells expressing the targeted Venus sensor ([Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"}). These data suggest that the levels of shRNAs produced from the miR-30-based vector may not be sufficient to be toxic to the cancer cells. Because expression levels of shRNAs are difficult to titer, we used siRNAs to determine the concentration of the toxic CD95L-derived siL3 required to kill HeyA8 cells ([Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}). Growth was effectively blocked (and cells died, data not shown) when siL3 was transfected at 1 nM---a concentration well below the commonly used and recommended siRNA concentration of 5--50 nM)---but not at 0.1 nM. These data suggest that this form of toxicity does not require high amounts of si- or shRNAs; however, the low expression we achieved from the miR-30 based shRNA vectors was not enough to effectively induce the toxicity. Because these miR-30-based shRNA vectors were developed to reduce off-target effects, the toxicity of CD95 and CD95L-targeting si/shRNAs described by us and others could be due to an OTE. While this was a plausible explanation, the high percentage of toxic si/shRNAs derived from CD95 and CD95L seemed to exclude a standard OTE and pointed at a survival activity of CD95 and CD95L.

We therefore tested whether exogenously added recombinant CD95L protein could protect cells from the toxicity of CD95L-derived shRNAs. When NB7 cells were incubated with different concentrations of a soluble form of CD95L (S2), toxicity exerted by shL1 was not affected ([Figure 1A](#fig1){ref-type="fig"}, left panel). NB7 neuroblastoma cells were chosen for these experiments because they lack expression of caspase-8 ([@bib66]) and hence are completely resistant to the apoptosis-inducing effects of CD95L. An ostensible moderate and dose-dependent protection was detected when cells were treated with a highly active leucine-zipper tagged CD95L (LzCD95L) ([Figure 1A](#fig1){ref-type="fig"}, center panel). However, this effect is likely due to the growth-promoting activities of soluble CD95L, which also significantly affected the growth of the cells expressing a scrambled control shRNA (seen for both S2 and LzCD95L). The recombinant LzCD95L protein was active, as demonstrated by its apoptosis-inducing capacity in CD95 apoptosis-sensitive MCF-7 cells ([Figure 1A](#fig1){ref-type="fig"}, right panel).

![Exogenous CD95L or CD95 proteins do not protect cells from toxicity of CD95L/CD95-derived shRNAs.\
(**A**) *Left:* Percent cell confluence over time of NB7 cells after infection with either pLKO-shScr or pLKO-shL1 and concurrent treatment with different concentrations of soluble CD95L protein (S2). Two-way ANOVA was performed for pairwise comparisons of % confluence over time between shScr expressing cells untreated (/) or treated with 100 ng/ml S2. Each data point represents mean ±SE of three replicates. *Center:* Percent cell confluence over time of NB7 cells after infection with either pLKO-shScr or pLKO-shL1 and concurrent treatment with different concentrations of leucine zipper-tagged (Lz)CD95L protein. Two-way ANOVA was performed for pairwise comparisons of % confluence over time between shScr-expressing cells untreated or treated with 50 ng/ml LzCD95L. Each data point represents mean ±SE of three replicates. *Right:* Percent nuclear PI staining of MCF-7 cells 24 hrs after adding different amounts of LzCD95L. (**B**) Schematic of the eight silent mutations introduced to the shL1 and the shL3 target sites of CD95L. (**C**) Western blot analysis of CD95L and β-actin in NB7 cells over-expressing CD95L-WT, CD95L-L1MUT, or CD95L-L3MUT 3 days after infection with pLKO-shScr, pLKO-shL1, or pLKO-shL3. Shown is one of two repeats of this analysis. (**D**) Percent nuclear PI staining of NB7 cells expressing empty pLenti vector, CD95L-WT, CD95L-L1MUT, or CD95L-L3MUT 6 days after infection with either pLKO-shScr, pLKO-shL1, or pLKO-shL3. Each bar represents mean ±SD of three replicates. (**E**) Schematic of the eight silent mutations introduced at the shR6 site of CD95. (F) Western blot analysis of CD95 and β-actin in MCF-7 cells over-expressing CD95-WT or CD95-R6MUT. (**G**) Percent nuclear PI staining of MCF-7 cells expressing empty pLNCX2 vector, CD95-WT, or CD95-R6MUT 6 days after infection with pLKO-shScr, pLKO-shR6, or pLKO-shR7. Each bar represents mean ±SD of three replicates.](elife-29702-fig1){#fig1}

To test whether CD95L or CD95 proteins could protect cancer cells from death, we introduced silent mutations into the targeted sites of three very toxic shRNAs: shL1, shL3 (both targeting CD95L) and shR6 (targeting CD95). We first introduced eight silent mutations into the sites targeted by either shL1 or shL3 ([Figure 1B](#fig1){ref-type="fig"}) and expressed these proteins in NB7 cells ([Figure 1C](#fig1){ref-type="fig"}). Both mutant constructs were highly resistant to knockdown by their cognate shRNA but still sensitive to knockdown by the other targeting shRNA ([Figure 1C](#fig1){ref-type="fig"}). Overexpression of these shRNA-resistant versions of the CD95L ORF did not protect the cells from shL1 or shL3, respectively ([Figure 1D](#fig1){ref-type="fig"}). Interestingly, expression of full length CD95L slowed down the growth of the NB7 cells right after infection with the lentivirus despite the absence of caspase-8 (data not shown). Infection with shRNAs was therefore performed 9 days after introducing CD95L when the cells had recovered and expressed significant CD95L protein levels ([Figure 1C](#fig1){ref-type="fig"}). We then mutated the CD95 mRNA in the targeted site of shR6 ([Figure 1E](#fig1){ref-type="fig"}). Neither expression of wild-type (wt) nor mutated (MUT) CD95 in MCF-7 cells ([Figure 1F](#fig1){ref-type="fig"}) reduced the toxicity when cells were infected with the pLKO-shR6 or another toxic lentiviral shRNA, pLKO-shR7 ([Figure 1G](#fig1){ref-type="fig"}). These data suggested that neither exogenously added recombinant CD95L or exogenously expressed CD95L or CD95 protein can protect cells from toxic shRNAs derived from these genes.

To determine whether we could prevent cancer cells from dying by this form of cell death by deleting the endogenous targeted sites, we used CRISPR/Cas9 gene-editing to excise sites targeted by different shRNAs and siRNAs in both alleles of the CD95 and CD95L genes. We first deleted a 41 nt piece of the CD95L gene in 293T cells, that contained the target site for shL3 ([Figure 2A and C](#fig2){ref-type="fig"}). While internal primers could not detect CD95L mRNA in three tested clones, primers outside of the deleted area did detect CD95L mRNA ([Figure 2D](#fig2){ref-type="fig"}, and data not shown). Three clones with this shL3 Δ41 deletion were pooled and tested for toxicity by shL3 expressed from a Tet-inducible plasmid (pTIP-shL3). Compared to a pool of control cells transfected only with the Cas9 plasmid, the 293T shL3 Δ41 cells were equally sensitive to the toxic shRNA ([Figure 2G](#fig2){ref-type="fig"}). This was also observed when the clones were tested individually (data not shown).

![CD95 and CD95L derived si/shRNAs kill cells in the absence of the targeted sites in CD95 or CD95L.\
(**A**) Schematic of the genomic locations and sequences of the gRNAs used to excise the siL3 (Δ64bp) and shL3 (Δ41bp) target sites from CD95L. PAM site is underlined. Green indicates a gRNA targeting the sense strand. Blue indicates a gRNA targeting the antisense strand. (**B**) Schematic showing the genomic locations and sequences of the gRNAs used to excise the shR6 (Δ227bp) target site. Mix, pool of three 293T clones with the homozygous shL3 deletion. (**C**) PCR with flanking (*top panels*) and internal (*bottom panels*) primers used to confirm the Δ41 deletion in the shL3 site in one of the three homozygous deletion 293T clones generated. Cells transfected with Cas9 only (Cas9) are wild-type. (**D**) Quantitative PCR for endogenous CD95L with a primer downstream of the Δ41 shL3 deletion and another primer internal to the deleted region. nd, not detectable. Each bar represents mean ±SD of three replicates. (**E**) PCR with flanking (*top row*) and internal (*bottom row*) primers used to confirm the presence of the shL3 Δ41 (*top panel*), siL3 Δ64 (*middle panel*), and shR6 Δ227 (*bottom panel*) deletions in HeyA8 clones. Mix, HeyA8 cells after transfection with Cas9 and gRNAs but before single cell cloning. (**F**) Quantitative PCR for CD95 in HeyA8 cells transfected with Cas9 plasmid (Cas9) alone, or the HeyA8 ΔshR6 clone \#11. RNA was extracted 5 days after infection with pLKO-shScr, pLKO-shR6, pLKO-shR2, or pLKO-shR6' (targeting the 3\'UTR). Each bar represents mean ±SD of three replicates. (**G**) Percent cell confluence over time of 293T cells (*left*) and a pool of three 293T clones with a homozygous deletion of the shL3 target site (*right*) infected with pTIP-shScr or pTIP-shL3 and treatment with or without Dox. Data are representative of two independent experiments. Each data point represents mean ±SE of six replicates. (**H**) *Left:* Percent confluence over time of HeyA8 cells infected with pLKO-shScr, pLKO-shR6, or pLKO-shL3. *Center:* Percent confluence over time of a HeyA8 clone with a homozygous deletion of the shR6 target site infected with either pLKO-shScr or pLKO-shR6. *Right:* Percent confluence over time of a pool of three HeyA8 clones with a homozygous deletion of the shL3 site infected with either pLKO-shScr or pLKO-shL3. Data are representative of two independent experiments. Each data point represents mean ±SE of three replicates. (**I**) Percent confluence over time of a pool of three HeyA8 clones harboring a homozygous deletion of the siRNA siL3 target site after transfection with different concentrations of siScr or siL3. Data are representative of three independent experiments. Each data point represents mean ±SE of three replicates.](elife-29702-fig2){#fig2}

To exclude the possibility that shL3 was inducing cell death due to a unique activity of shL3 and/or 293T cells, we deleted the same 41 nt in CD95L in the ovarian cancer cell line HeyA8; We also generated HeyA8 clones in which we either removed a 64 nt region containing the target site for the siRNA siL3 in the CD95L coding sequence or a 227 nt region containing the target site for shR6 in CD95 ([Figure 2A and B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In all cases, homozygous deletions were generated ([Figure 2E](#fig2){ref-type="fig"}). To confirm the deletion of the shR6 target site, we infected HeyA8 cells treated with the Cas9 plasmid only and HeyA8 with a homozygous deletion of the shR6 site with shR6 and, as positive controls, with shR2 (targeting the CD95 ORF) and shR6\' (targeting the CD95 3\'UTR). Five days after infection, CD95 mRNA was quantified by real time PCR using a primer located outside the 227 bp deletion ([Figure 2F](#fig2){ref-type="fig"}). The mutated CD95 mRNA was still detectable in the shR6 Δ227 cells. While shR2 and shR6\' (both targeting outside the deleted region) caused knockdown of CD95 mRNA in both the Cas9 control and the shR6 Δ227 cells, shR6 could only reduce mRNA expression in the Cas9 control cells. These data document that HeyA8 CD95 shR6 Δ227 cells no longer harbor the sequence targeted by shR6.

Now having HeyA8 cells lacking one of three RNAi-targeted sites in either CD95 or CD95L, we could test the role of the CD95 and CD95L gene products in protecting HeyA8 cells from the death induced by either shRNA (shL3 and shR6, two different vectors: pLKO or the Tet inducible pTIP) or the siRNA siL3. In all cases, the shRNA or siRNA that targeted the deleted region was still fully toxic to the target-site deleted cells ([Figure 2H and I](#fig2){ref-type="fig"}). We saw efficient growth reduction and cell death in siL3 site-deleted cells transfected with as little as 1 nM siL3 ([Figure 2I](#fig2){ref-type="fig"}, and data not shown). These data firmly establish that cells were not dying due to the knockdown of either CD95 or CD95L.

Involvement of canonical RNAi {#s2-2}
-----------------------------

shRNAs and early generation naked siRNAs showed general toxicity when introduced in large amounts, presumably by eliciting an interferon (IFN) response ([@bib43]) or by saturating the RISC ([@bib20]). However, both chemically modified siRNAs at very low concentrations and lentiviral shRNAs at an MOI \<1 were still toxic (data not shown). We therefore decided to test whether the observed toxicity involved canonical RNAi and activity of the RISC. To test shRNAs or siRNAs targeting CD95L, we introduced the Venus-CD95L sensor (inset in [Figure 3A](#fig3){ref-type="fig"}, right panel) into HeyA8 CD95 protein k.o. cells we had generated in the process of deleting the shR6 site ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, clone \#2 was used for the following studies; see figure legend for strategy and characterization of the clones). While double-stranded (ds)-siL3 effectively silenced Venus expression and induced toxicity, neither the sense nor the antisense single-stranded (ss)RNAs significantly decreased Venus expression or induced toxicity ([Figure 3A](#fig3){ref-type="fig"}). In addition, no activity was found when ds-siL3, synthesized as deoxyribo-oligonucleotides, was transfected into the cells ([Figure 3B](#fig3){ref-type="fig"}). Using this type of analysis, we tested a number of modified siRNAs for RNAi activity and toxicity. For siRNAs to be fully active, they require 3\' overhangs on both strands ([@bib5]). Converting siL3 to a blunt-end duplex resulted in substantial loss of RNAi activity and toxicity ([Figure 3C](#fig3){ref-type="fig"}). Due to the topology of the RISC, siRNA activity is decreased by modification of the 5' end of the antisense/guide strand ([@bib13]). To test whether cell death induced by siL3 would be affected by a bulky modification, we placed a Cy5 moiety at any of the four possible ends of the siL3 duplex. Only when the siL3 duplex carried a 5' modification in the guide strand did it prevent RNAi activity and toxicity; modifications in the three other positions had no effect ([Figure 3C](#fig3){ref-type="fig"}). This was confirmed for another siRNA, siL2. To test whether the toxicity of siL3 required association with a macromolecular complex, which would be consistent with RISC involvement, we performed a competition experiment. HeyA8 cells were transfected with 10 nM of siL3, and a mutated nontoxic oligonucleotide, siL3MUT, was titered in ([Figure 3D](#fig3){ref-type="fig"}). siL3MUT reduced the growth inhibitory activity of siL3 in a dose-dependent fashion suggesting that siL3 and siL3MUT compete for the same binding site in the cells, pointing at involvement of the RISC.

![Toxicity of CD95L-derived siRNAs involves canonical RNAi activity.\
(**A**) Percent cell confluence (*left*) and total green object integrated intensity (*right*) over time of a HeyA8 CD95 knockout clone (ΔR6 cl\#2) expressing the Venus-CD95L sensor either untreated (Ctr) or after transfection with 25 nM of single-stranded sense, single-stranded antisense, or double-stranded (ds) siScr or siL3 siRNAs. The CD95L sensor is schematically shown and comprises the Venus ORF fused to the CD95L ORF lacking the A of the ATG start codon (X). Data are representative of two independent experiments. Each data point represents mean ±SE of three replicates. (**B**) Percent cell confluence (*left*) and total green object integrated intensity (*right*) over time of the HeyA8 CD95L sensor cell used in [Figure 3A](#fig3){ref-type="fig"} after transfection with 5 nM siScr or siL3 double-stranded RNA (dsRNA) or double-stranded DNA (dsDNA). Data are representative of two independent experiments. Each data point represents mean ±SE of three replicates. (**C**) Summary of experiments to test whether siL3 and siL2 siRNAs modified as indicated (*left*) were active (check mark) or not (X) in reducing green fluorescence or cell growth (both \>70% reduction at end point) when transfected at 25 nM (except for blunt end oligonucleotides which were used at 5 nM and compared to 5 nM of siL3) into HeyA8 CD95L sensor cells used in [Figure 3A](#fig3){ref-type="fig"}. Endpoints were 164 hrs for blunt end siRNA transfection, 180 hrs for modified siL3 and 144 hrs for modified siL2 siRNA transfections. Every data row is based on cell growth and green fluorescence quantification data executed as shown in **A**. Each analysis was done in triplicate and based on two independent repeats. (**D**) Red object count over time of HeyA8 cells (expressing NucRed) after transfection with different ratios of siL3 and mutant siL3 (siL3MUT). Data are representative of two independent experiments. Each data point represents mean ±SE of three replicates. (**E**) Percent cell confluence over time of HCT116 parental (*left*) or Dicer^-/-^ (clone \#43, another Dicer^-/-^ clone, \#45, gave a similar result, data not shown), or Drosha^-/-^ (*right*) cells after infection with either shScr, shL3 or shR6 pLKO viruses. Inserts show the level of protein expression levels of Drosha/Dicer and AGO2 levels in the tested cells. Data are representative of three independent experiments. Each data point represents mean ±SE of four replicates. Drosha^-/-^ cells were more sensitive to toxic shRNAs than wt cells (p\<0.0001, according to a polynomial fitting model). (**F**) Western blot analysis of HCT116 wt, Dicer^-/-^ or Drosha^-/-^ cells 4 days after infection with either pLKO-shScr or pLKO-shR6. (**G**) Percent cell confluence over time of HCT116 wt, Dicer^-/-^ (clone \#43) and Drosha^-/-^ cells after transfection with 25 nM siScr or siL3. Data are representative of four independent experiments (Dicer^-/-^ clone \#45, gave a similar result, data not shown). Each data point represents the mean ±SE of four replicates. Data in insert confirm similar uptake of transfected siRNA (25 nM of siGLO Red) into wild-type, Dicer^-/-^ and Drosha^-/-^ cells. Dicer^-/-^ and Drosha^-/-^ cells were more sensitive to siL3 than wt cells (p\<0.0001, according to a polynomial fitting model). (**H**) Percent reduction in Venus expression (green) and in cell number (red object count \[red\]) over time of HeyA8 cells expressing the Venus-CD95L sensor and red nuclei after transfection with 5 nM of different chimeric siRNAs generated by substituting nucleotides in the toxic siL3 with the scrambled siRNA sequence beginning at either the seed match end (top) or the opposite end (bottom) of siL3 after 188 hr. The schematic in the middle shows the sequence of siL3 and the siScr siRNA (both sense and antisense strands). The 6mer seed sequence region of siL3 (positions 2 to 7) is highlighted in light blue. Nucleotides shared by siScr and siL3 are shown in grey font. Data are representative of two independent experiments. Each data point represents mean of three replicates. In another independent experiment cells were transfected with 25 nM with a very similar result (data not shown).](elife-29702-fig3){#fig3}

To determine involvement of RNAi pathway components in the toxicity of CD95 and CD95L-derived sequences, we tested HCT116 cells deficient for either Drosha or Dicer ([@bib35]). Growth of parental HCT116 cells was impaired after infection with shL3 or shR6 viruses ([Figure 3E](#fig3){ref-type="fig"}, left panel). Consistent with the requirement of Dicer to process shRNAs, Dicer^-/-^ cells were completely resistant to the toxic shRNAs ([Figure 3E](#fig3){ref-type="fig"}, center panel). This was also supported by the inability of shR6 to silence CD95 protein expression in these cells ([Figure 3F](#fig3){ref-type="fig"}). Dicer^-/-^ cells were not resistant to toxic siRNAs as these cells died when transfected with siL3, which is consistent with mature siRNAs not needing further processing by Dicer ([Figure 3G](#fig3){ref-type="fig"}, center panel). Interestingly, Drosha^-/-^ cells were hypersensitive to the two toxic shRNAs ([Figure 3E](#fig3){ref-type="fig"}, right panel, p\<0.0001, according to a polynomial fitting model), and shR6 efficiently knocked down CD95 expression in Drosha^-/-^ cells ([Figure 3F](#fig3){ref-type="fig"}). Both Drosha^-/-^ and Dicer^-/-^ cells were much more susceptible to the toxicity induced by siL3 than parental cells ([Figure 3G](#fig3){ref-type="fig"}, center and right panel, p\<0.0001, according to a polynomial fitting model). The hypersensitivity of the Drosha^-/-^ cells to toxic si/shRNAs and of Dicer^-/-^ cells to toxic siRNAs can be explained by Drosha^-/-^ and Dicer^-/-^ cells allowing much more efficient uptake of mature toxic RNAi-active species into the RISC because they are almost completely devoid of competing endogenous miRNAs ([@bib35]).

To determine the contribution of the siRNA seed sequence to their toxicity, we generated a set of chimeric siRNAs in which we systematically replaced nucleotides of the toxic siL3 siRNA with nucleotides of a nontoxic scrambled siRNA. We did this starting either from the seed end or from the opposite end ([Figure 3H](#fig3){ref-type="fig"}). HeyA8 cells expressing both the Venus-CD95L sensor (to monitor level of knockdown) and a Nuc-Red plasmid to fluorescently label nuclei (to monitor the effects on cell growth) were transfected with 5 nM of the chimeric siRNAs; total green fluorescence and the number of red fluorescent nuclei were quantified over time. The siL3 control transfected cells showed an almost complete suppression of the green fluorescence and high toxicity. In the top panel of [Figure 3H](#fig3){ref-type="fig"}, the data are summarized in which siL3 nucleotides were stepwise replaced with siScr nucleotides from the seed sequence end. Both RNAi and toxicity were profoundly reduced when three of the terminal siL3 nucleotides were replaced with the siScr nucleotides in those positions, suggesting the seed region (6mer highlighted in blue) is critical for both activities. Consistently, as shown in the bottom panel of [Figure 3H](#fig3){ref-type="fig"}, when siL3 nucleotides were replaced with siScr nucleotides from the non-seed end, neither RNAi nor the toxicity was diminished until replacements affected residues in the seed region. These data suggest the 6mer seed sequence of siL3 was critical for both RNAi activity and its toxicity.

Toxic si/shRNAs cause downregulation of survival genes {#s2-3}
------------------------------------------------------

A general OTE by RNAi has been described ([@bib6]; [@bib30]; [@bib39]). However, this was been reported to cause toxicity in most cases, and the targeted mRNAs were difficult to predict ([@bib6]). The fact that 22 of the tested CD95 and CD95L-targeting sh- and si/DsiRNAs were toxic to many cancer cells evoking similar morphological and biological responses ([@bib26]) generated a conundrum: Could an OTE trigger a specific biology? To test this, we expressed two toxic shRNAs - one targeting CD95L (shL3) and one targeting CD95 (shR6) - in cells lacking their respective target sequences and subjected the RNA isolated from these cells to an RNA-Seq analysis. In order to detect effects that were independent of cell type, delivery method of the shRNA, or targeted gene, we expressed shL3 in 293T (ΔshL3) cells using the Tet-inducible vector pTIP and shR6 in HeyA8 (ΔshR6) cells using the pLKO vector. In each case, changes in RNA abundance were compared to cells expressing a non-targeting shRNA in matching vectors. Total RNA was harvested in all cases at either the 50 hr time point (before the onset of cell death) or at the 100 hr time point (during cell death) ([Figure 4A](#fig4){ref-type="fig"}). To achieve high stringency, the data were then analyzed in two ways: first, using a conventional alignment-based analysis to identify genes for which the mRNA changed more than 1.5-fold (and an adjusted p-value of less than 0.05) and second, by a read-based method, in which we first identified all reads that changed \>1.5 fold and then subjected each read to a BLAST search to identify the gene it was derived from. Only RNAs that were detected by both methods were considered ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The combination of the analyses resulted in one mRNA that was upregulated and 11 mRNAs that were downregulated ([Figure 4B](#fig4){ref-type="fig"}). Using an arrayed qPCR approach, most of these detected mRNA changes were validated for both cell lines ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Interestingly, for nine of the eleven genes, published data suggest they are either highly upregulated in cancer and/or critical for the survival of cancer cells, as their inhibition or knockdown resulted in either growth reduction or induction of various forms of cell death (see legend of [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} for details). Significantly, six of these eleven downregulated genes were recently identified in two independent genome-wide lethality screens to be critical for cancer cell survival ([@bib7]; [@bib70]) ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Considering these two screens only identified 6.6% of human genes to be critical for cell survival, we found a significant enrichment (54.5%, p-value=3×10^−6^ according to binomial distribution) of these survival genes among the genes downregulated during the cell death induced by either shL3 or shR6. All six survival genes are either highly amplified or mutated in human cancers ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). In addition to these six genes, GNB1 and HIST1H1C were reported to be required fitness genes in a recent high-resolution CRISPR-based screen ([@bib28]). A kinetic analysis showed most of the deregulated mRNAs were downregulated early with a significant effect already at 14 hr, more than two days before the onset of cell death ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"} and data not shown). This suggested the cells were dying because of the silencing of multiple critical survival genes, providing an explanation for why multiple cell death pathways were activated. We therefore call this type of cell death DISE (for Death Induced by Survival gene Elimination).

![Toxic shRNAs derived from CD95 and CD95L cause downregulation of critical survival genes.\
(**A**) Schematic of RNA-Seq work flow for total RNA sample prepared both before (50 hr) and during (100 hr) DISE after expressing either shR6 or shL3 from different vector systems (i.e. pLKO-shR6 and pTIP-shL3) in different cells (HeyA8 shR6 Δ227 cells and 293T shL3 Δ41 cells). (**B**) One mRNA was up and 11 mRNAs were downregulated in the cells treated with toxic shL3 and shR6 as shown in [Figure 4A](#fig4){ref-type="fig"}. mRNAs shown in red were found to be essential cancer survival genes in two genome-wide lethality screens. The number of essential genes was enriched from 6.6% of the tested genes ([@bib7]; [@bib70]) to 54.5% in our study (p=3×10^−6^ according to binomial distribution). (**C**) The level of growth inhibition observed in HeyA8 cells transfected with siRNA SmartPools (25 nM) individually targeting the listed survival genes. Targeting the seven genes shown significantly reduced cell growth compared to cells transfected with a siScr pool at 140 hrs (samples done in quadruplicate in two independent experiments) with an ANOVA p\<0.05. (**D**) Gene set enrichment analysis for a group of 1846 survival genes (*top four panels*) and 416 nonsurvival genes (*bottom four panels*) identified in a genome-wide CRISPR lethality screen ([@bib70]) after introducing Dox-inducible shL3 in 293T ΔshL3 cells (*left-most panels*), shR6 in HeyA8 ΔshR6 cells (*center-left panels*), shL1 in parental 293T cells (*center-right panels*), and siL3 in HeyA8 cells (*right-most panels*). Scrambled sequences served as controls. p-values indicate the significance of enrichment. (**E**) Schematics showing all RNAs at least 1.5 fold downregulated (adj p-value\<0.05) in cells treated as in [Figure 4A](#fig4){ref-type="fig"}. Histones that are underlined contain a 3'UTR. (**F**) Metascape analysis of the 4 RNA Seq data sets analyzed. The boxed GO term clusters were highly enriched in all data sets.](elife-29702-fig4){#fig4}

To confirm some of the downregulated genes were also critical survival genes for HeyA8 cells, we transfected HeyA8 cells with siRNA SmartPools targeting each of the eleven genes. Individual knockdown of seven of the targeted genes resulted in reduced cell growth when compared to cells transfected with a pool of scrambled siRNAs ([Figure 4C](#fig4){ref-type="fig"}). To mimic the effect of the CD95 and CD95L-derived shRNAs, we treated HeyA8 cells with a combination of siRNA pools targeting these seven genes. Remarkably, 1 nM of this siRNA mixture (35.7 pM of each individual siRNA) was sufficient to effectively reduce growth of the cells ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}) and also cause substantial cell death ([Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}), suggesting it is possible to kill cancer cells with very small amounts of siRNAs targeting a network of these survival genes.

To test the generality of this phenomenon, we inducibly expressed another CD95L derived shRNA, shL1, in 293T cells using the pTIP vector, and transfected HeyA8 cells with 25 nM siL3. We subjected the cells to RNA-Seq analysis 100 hrs and 48 hrs after addition of Dox or after transfection, respectively. To determine whether survival genes were downregulated in all cases of sh/siRNA-induced cell death, we used a list of 1882 survival genes and 423 genes not required for survival (nonsurvival genes) recently identified in a CRISPR lethality screen ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). We subjected the four ranked RNA-Seq data sets to a gene set enrichment analysis using the two gene sets ([Figure 4D](#fig4){ref-type="fig"}). In all cases, survival genes were significantly enriched towards the top of the ranked lists (most downregulated). In contrast, nonsurvival genes were not enriched. One interesting feature of DISE that emerged was the substantial loss of histones. Of the 16 genes that were significantly downregulated in cells treated with any of the four sh/siRNAs, 12 were histones ([Figure 4E](#fig4){ref-type="fig"}). While it might be expected that dying cells would downregulate highly expressed genes such as histones, we believe that losing histones is a specific aspect of DISE because a detailed analysis revealed the downregulated histones were not the most highly expressed genes in these cells ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). In addition, almost as many genes with similarly high expression were found to be upregulated in cells after DISE induction.

A Metascape analysis revealed genes involved in mitotic cell cycle, DNA conformation change, and macromolecular complex assembly were among the most significantly downregulated across all cells in which DISE was induced by any of the four sh/siRNAs ([Figure 4F](#fig4){ref-type="fig"}). These GO clusters are consistent with DISE being a form of mitotic catastrophe with cells unable to survive cell division ([@bib26]) and suggest a general degradation of macromolecular complexes.

Toxic si/shRNAs target survival genes in their 3\'UTR {#s2-4}
-----------------------------------------------------

To test whether the toxic shRNAs directly targeted genes through canonical RNAi, we subjected the two gene lists obtained from the RNA-Seq analysis (the cell lines treated with either shL3 or shR6 at the 50 hr time point) to a Sylamer analysis ([@bib69]) designed to find an enrichment of miRNA/siRNA-targeted sites in the 3\'UTR of a list of genes ranked according to fold downregulation ([Figure 5A](#fig5){ref-type="fig"}). This analysis identified a strong enrichment of the cognate seed match for shL3 and shR6 in cells treated with either of these two shRNAs. The analyses with cells treated with shRNAs for 100 hrs looked similar but less significant, suggesting early targeting by the shRNAs followed by secondary events (data not shown). Enrichment in 6mers and 8mers were both detected (only 8mers shown) in the 3\'UTRs but not the ORF of the ranked genes (data not shown).

![DISE inducing si/shRNAs target critical survival genes through RNAi.\
(**A**) Sylamer plots for the list of genes in the shL3 experiment (left) and the shR6 experiment (right) ordered from down-regulated to up-regulated. The most highly enriched sequence is shown which in each case is the 8mer seed match of the introduced shRNA. The red line corresponds to a p-value threshold of 0.05 after Bonferroni correction for the number of words tested (65536). Bonferroni-adjusted p-values are shown. The unadjusted p-values are 1.58E-24 and 1.35E-26, respectively. The black line represents the sequences carrying the let-7 8mer seed match. (**B**) Location of the 6mer seed matches of either shL3 or shR6 in the 3\'UTRs of the 11 genes (shown at scale) identified in the RNA-Seq experiment described in [Figure 4A](#fig4){ref-type="fig"}. Red font indicates a critical survival gene. (**C**) A series of six 2 × 2 contingency tables comparing whether or not a critical survival gene is downregulated after treatment with the indicated siRNA or shRNA to whether or not its 3'UTR contains at least one seed match for the introduced sh/siRNA. p-values were calculated using Fisher's Exact Test to determine any significant relationship between gene downregulation and presence of seed matches in 3'UTR.](elife-29702-fig5){#fig5}

Interestingly, the seed matches detected by the Sylamer analysis were shifted by one nucleotide from the expected seed match based on the 21mer coded by the lentivirus. RNA-Seq analysis performed for the small RNA fraction confirmed in all cases (shScr and shL3 in pTIP, and shScr and shR6 in pLKO), the shRNAs in the cells were cleaved in a way resulting in the predominant formation of an siRNA shifted one nucleotide away from the shRNA loop region (black arrow heads in [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). This allowed us to design toxic mature siRNAs based on the sequences of shL3 and shR6. These shRNA-to-siRNA converts were toxic to HeyA8 cells ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) confirming that the observed toxicity was not limited to the TRC shRNA platform, but based on a sequence-specific activity of the si/shRNAs.

The generalizability of the Sylamer results for shL3 and shR6 was tested with cells treated with either shL1 or siL3. In both cases, when the ranked RNA Seq data were subjected to a Sylamer analysis, the seed matches of the si/shRNA introduced were again significantly enriched in the 3\'UTR of downregulated RNAs ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). In none of the Sylamer analyses of the four data sets, did we see enrichment of seed matches in the 3\'UTRs of downregulated RNAs that matched the passenger strand. In all cases, the only significantly enriched sequences matched the seed sequences in the guide strand of the si/shRNAs we introduced.

Our data suggested that DISE inducing si/shRNAs caused an early loss of survival genes, and at the same time downregulated RNAs through canonical RNAi targeting their 3\'UTR. However, it was not clear whether the most highly downregulated survival genes were targeted in their 3\'UTR by RNAi-active sequences. We determined as little as six nucleotides dictated whether an siRNA killed cancer cells (see [Figure 3H](#fig3){ref-type="fig"}). 10 of the 11 downregulated genes identified in the RNA-Seq analysis described in [Figure 4A and B](#fig4){ref-type="fig"} contained multiple 6mer seed matches for either shL3 and/or shR6 ([Figure 5B](#fig5){ref-type="fig"}). It is therefore likely the two shRNAs, shL3 and shR6, killed cells by targeting a network of genes enriched in critical survival genes through RNAi. The only gene without an shL3 or shR6 seed match was HIST1H1C. Interestingly, only four of the histones downregulated in cells after treatment with any of the four tested si/shRNAs had a 3\'UTR (underlined in [Figure 4E](#fig4){ref-type="fig"}) suggesting that most histones were not directly targeted by the si/shRNAs.

Using arrayed qPCR, we tested whether other toxic shRNAs targeting either CD95 or CD95L also caused downregulation of some of the 11 genes silenced by shL3 and shR6. HeyA8 cells were transfected with the toxic siRNA siL3 (RNA harvested at 80 hrs) or the toxic shRNAs shL1, shL3 or shR7 (RNA harvested at 100 hrs). While shL1 did not have much of an effect on the expression of these genes, shR7 caused downregulation of 7 of 11 of the same genes targeted by shL3 even though the 6mer seed matches of the two shRNAs are very different (CTTTGT for shL3 and GGAGGA for shR7) ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}).

To determine whether preferential targeting of survival genes was responsible for the death of the cells, we tested whether there was an association between the presence or absence of a predicted seed match in the 3\'UTR for the si/shRNA introduced and whether a gene would be downregulated (\>1.5 fold downregulated, p\<0.05) among survival genes using the Fisher\'s Exact test ([Figure 5C](#fig5){ref-type="fig"}). In almost all cases, this analysis revealed that survival genes containing a predicted seed match in their 3\'UTR were statistically more likely to be downregulated than survival genes without such a motif. The analysis with shL1 treated cells did not reach statistical significance, likely due to the fact that this shRNA was found to be very toxic and the 100 hr time point may have been too late to observe evidence of significant targeting. This interpretation is supported by the observation that the significance for both shL3 and shR6 to target survival genes was higher at 50 hrs when compared to the 100 hr time points ([Figure 5C](#fig5){ref-type="fig"}) and that the Sylamer analysis of the shL1 treated cells was less significant after 100 hrs of treatment than any of the other Sylamer analyses ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

Now that we had established that the toxicity of the studied shRNAs involved targeting of survival genes rather than CD95 or CD95L, we had to assume that when studying a larger set of shRNAs that the level of knockdown of the targeted genes and the toxicity were not strictly correlated. This was confirmed for the TRC shRNAs targeting the ORF or 3\'UTR of CD95 in CD95 high expressing HeyA8 cells ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). While some of the toxic shRNAs efficiently silenced CD95 (i.e. shR6 and shR2) few did not (i.e. shR5). In summary, our analyses suggest that cells die by DISE due to an early and selective silencing of survival genes through targeting seed matches in their 3\'UTR followed by the downregulation of histones.

Identification of toxic shRNAs in the CD95L and CD95 mRNAs {#s2-5}
----------------------------------------------------------

The majority of commercially available si-, Dsi-, and shRNAs targeting either CD95 or CD95L were highly toxic to cancer cells. We therefore asked whether these two genes contained additional sequences with similar activity. To test all shRNAs derived from either CD95L or CD95, we synthesized all possible shRNAs, 21 nucleotides long, present in the ORF or the 3\'UTR of either CD95L or CD95 starting with the first 21 nucleotides after the start codon, and then shifting the sequence by one nucleotide along the entire ORF and 3\'UTR ([Figure 6A](#fig6){ref-type="fig"}). We also included shRNAs from a gene not expressed in mammalian cells and not expected to contain toxic sequences, Venus. All 4666 oligonucleotides (700 Venus, 825 CD95L ORF, 837 CD95L 3\'UTR, 987 CD95 ORF, and 1317 CD95 3\'UTR shRNAs) were cloned into the Tet-inducible pTIP vector ([Figure 6B](#fig6){ref-type="fig"}) as five individual pools. We first tested the activity of each individual pool to be toxic and to target the Venus sensor protein (fused to either the ORF of CD95 or CD95L). NB7 cells were again used because of their resistance to the Venus-CD95L sensor, which was found to be slightly toxic to CD95 apoptosis competent cells. NB7-Venus-CD95L cells infected with the Venus-targeting shRNA pool showed some reduction in fluorescence when Dox was added, however, the shRNA pool derived from the CD95L ORF was much more active in knocking down Venus ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). No significant green fluorescence reduction was detected in cells after infection with the shRNA pool derived from the CD95L 3\'UTR since the targeted sequences were not part of the sensor. Similar results were obtained when NB7-Venus-CD95 cells were infected with the Venus, CD95 ORF, and CD95 3\'UTR targeting shRNA pools. To determine their ability to reduce cell growth (as a surrogate marker for toxicity), we infected NB7 parental cells with each of the five pools (parental cells were used for this experiment to avoid a possible sponge effect by expressing either CD95L or CD95 sequences that were part of the Venus sensors). Interestingly, the pool of 700 shRNAs derived from Venus did not cause any toxicity ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). In contrast, the pool of the shRNAs derived from CD95L significantly slowed down growth, while no toxicity was observed when cells were infected with the pool of shRNAs derived from the CD95L 3\'UTR. In the case of CD95, both the shRNAs derived from the ORF and the 3\'UTR showed some toxicity. However, the shRNAs derived from the 3\'UTR caused greater toxicity compared to those derived from the ORF. The data suggest that overall the shRNAs derived from the CD95L ORF and the CD95 3\'UTR contain the most toxic sequences.

![Identifying all toxic shRNAs derived from CD95L and CD95.\
(**A**) Schematic showing the cloned shRNAs covering the ORF of Venus and the ORFs and 3\'UTRs of CD95L and CD95. The 3'UTR is displayed as a dashed line because it was not included in the full-length Venus-CD95L/CD95 sensors. (**B**) Work-flow of pTIP-shRNA library synthesis, shRNA screen and data analysis. (**C**) Ranked fold reduction of shRNAs spanning Venus and CD95L (ORF and 3\'UTR) (*left three panels*) and Venus and CD95 (ORF and 3\'UTR) (*right three panels*). The ranked lists were separated into the shRNAs derived from Venus (top), the ORFs (center) and the 3\'UTRs (bottom). The p-value of enrichment for each ranked set of shRNAs is given. Only the parts of the ranked lists are shown with the downregulated shRNAs. For all six panels, the top section of each panel (boxed in blue) contains the data on shRNAs downregulated after infection of cells and cultured for 9 days without Dox when compared to the composition of the shRNA plasmid library and the bottom half (boxed in orange) contains the data on shRNAs downregulated after culture with Dox for 9 days when compared to the culture without Dox. P-values were calculated using Mann Whitney U tests with a one-sided alternative that the rank was lower. (**D**) The location of all shRNAs significantly downregulated at least five fold along the sequences of Venus, CD95L ORF, CD95L 3\'UTR (left panel) and Venus, CD95 ORF, and CD95 3\'UTR (right panel). The top half of each sub panel (blue ticks) shows the shRNAs downregulated after infection and the bottom half (orange ticks) contains the data on shRNAs downregulated after culture with Dox for 9 days. Significance of enrichment in the different subpanels is shown. p-values were calculated according to statistical tests of two proportions. Each data set was compared to the corresponding Venus distribution. Green line: sequence that corresponds to the intracellular domain of CD95L.](elife-29702-fig6){#fig6}

To determine the toxicity of each of the shRNAs in the pools, NB7 cells were infected with the libraries of shRNA viruses (MOI \<1), and after puromycin selection cells were pooled 1:1:1 (Venus ORF/CD95L ORF/CD95L 3\'UTR pools or Venus ORF/CD95 ORF/CD95 3\'UTR pools) to allow for competition between shRNAs when Dox was added ([Figure 6B](#fig6){ref-type="fig"}). Cells were cultured for 9 days with and without Dox to allow for cell death to occur. To identify depleted shRNAs, shRNA barcodes were detected through next generation sequencing of PCR products to determine the relative abundance of each shRNA in three pools: 1) the cloned plasmid libraries, 2) cells after infection and culture for 9 days without Dox, and 3) cells infected and cultured with Dox for 9 days. A total of 71,168,032 reads were detected containing a complete sequence of one of the cloned shRNAs. Virtually all shRNAs were substantially represented in the cloned plasmids ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). The shRNAs in the CD95L pool (comprised of the Venus, CD95L ORF, and CD95L 3'UTR subpools) and the CD95 pool (comprised of the Venus, CD95 ORF, and CD95 3'UTR subpools) were ranked from highest (most toxic) to lowest underrepresentation. During this and subsequent analyses, we noticed in many cases, Dox addition did cause a reduction of shRNAs, indicating an increase in toxicity; however, in other instances, infection alone and without the addition of Dox was toxic. This effect was likely due to the well-described leakiness of the Tet-on system ([@bib53]), which we confirmed for shR6 in NB7 cells ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). To capture all toxic shRNAs, we therefore decided to split the analysis into two halves: 1) the changes in abundance after infection compared to the composition in the plasmid pool (infection -Dox) and 2) the changes in abundance after Dox addition compared to the infected --Dox cells (infection +Dox). In subsequent analyses, shRNAs underrepresented after infection are either boxed ([Figure 6C](#fig6){ref-type="fig"}) or shown ([Figures 6D](#fig6){ref-type="fig"} and [7B](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}) in blue and the ones underrepresented after Dox addition are either boxed or shown in orange. The results for all shRNAs are shown in [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}. Grey dots represent all shRNAs and red dots represent only the ones that were significantly underrepresented at least 5-fold. Interestingly, the highest abundance of downregulated shRNAs was found in the CD95L ORF and the CD95 3\'UTR pools of shRNAs, which is consistent with the increased toxicity observed when NB7 cells were infected with either of these two pools individually (see [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). The shRNAs of these two toxic pools were highly enriched in the underrepresented shRNAs in the two pooled experiments (CD95L and CD95). Their toxicity was also evident when all shRNAs in each pool (2362 shRNAs in the CD95L and 3004 shRNAs in the CD95 pool) were ranked according to the highest fold downregulation ([Figure 6C](#fig6){ref-type="fig"}). The three subpools in each experiment are shown separately. Thus, again this analysis identified the ORF of CD95L and the 3\'UTR of CD95 as the subpool in each analysis with the highest enrichment of underrepresented shRNAs ([Figure 6C](#fig6){ref-type="fig"}).

![In silico prediction of DISE activity tracks with experimental determined toxicity of shRNAs.\
(**A**) *Left:* Schematic showing the preferential targeting of seed matches present in the 3\'UTRs (red marks) of survival genes by toxic si/shRNAs. *Right:* The toxicity index (TI) is the normalized ratio of the number of 6mer or 8mer seed matches present in a list of survival genes versus a list of nonsurvival genes. (**B**) Fold downregulation versus ranked (8mer seed matched based) Toxicity Index for shRNAs of the Venus/CD95L pool (*left three panels*) and the Venus/CD95 pool (*right three panels*). Orange and blue tick marks indicate the same as in [Figure 6D](#fig6){ref-type="fig"}. To test if higher TI is enriched in shRNAs that were highly downregulated, p-values were calculated based on permutated datasets using Mann-Whitney U tests. The ranking of TI was randomly shuffled 10,000 times and the W statistic from our dataset was compared to the distribution of the W statistic of the permutated datasets. (**C, D**) Plot of fold downregulation of toxic shRNAs derived from CD95L ORF of the toxicity screens -Dox (left) or +Dox (center) versus GC content the 6mer seed in each shRNA. (**E**) Plot of the log(TI) of all 4092 possible 6mers versus GC content of the seeds. Pearson correlation coefficient and significance (p values) are given.](elife-29702-fig7){#fig7}

This analysis allowed us to describe the toxicity landscape of CD95L and CD95 ORFs and their 3\'UTRs ([Figure 6D](#fig6){ref-type="fig"}). All shRNAs significantly underrepresented at least five-fold (red dots in [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}) are shown along the CD95L pool ([Figure 6D](#fig6){ref-type="fig"}, left) and the CD95 pool ([Figure 6D](#fig6){ref-type="fig"}, right) sequences. For both CD95L and CD95, toxic shRNAs localized into distinct clusters. The highest density of toxic sequences was found in the stretch of RNA that codes for the intracellular domain of CD95L (underlined in green in [Figure 6D](#fig6){ref-type="fig"}).

Predicting shRNA toxicity - the toxicity index (TI) and GC content {#s2-6}
------------------------------------------------------------------

Our data suggest toxic shRNAs derived from either CD95L or CD95 kill cancer cells by targeting a network of genes critical for survival through canonical RNAi. Therefore, we wondered how many 8mer seed sequences derived from these toxic shRNAs would have corresponding seed matches in the 3\'UTR of critical survival genes in the human genome. Would it be possible to predict with some certainty in an *in silico* analysis what shRNAs would be toxic to cells? To calculate such a hypothetical toxicity index, we used the ranked CRISPR data set ([@bib70]) with 1882 survival genes (SGs) and 423 nonSGs. Based on our RNA-Seq analyses, we hypothesized the survival genes contained more putative seed matches for toxic shRNAs in their 3\'UTRs than the nonsurvival genes ([Figure 7A](#fig7){ref-type="fig"}, left) and that the number of seed matches in the 3\'UTRs of survival genes divided by the number of seed matches in the 3\'UTR of nonsurvival genes would, to some extent, predict toxicity of an si/shRNA ([Figure 7A](#fig7){ref-type="fig"}, right).

To establish a Toxicity Index (TI) for each shRNA, we first gathered 3'UTR sequences for 1846 of the survival genes and 416 of the nonsurvival genes. We then generated a list containing a normalized ratio of occurrences of every possible 8mer seed match in the 3\'UTRs of the survival and non-survival gene groups. This resulted in a ratio for each of the 65,536 possible 8mer combinations ([Supplementary file 4](#supp4){ref-type="supplementary-material"}), the TI. We then assigned to each of the 4666 shRNAs in our screen its TI, and ranked each pool within the two experiments of our screen according to the highest TI (red stippled lines in [Figure 7B](#fig7){ref-type="fig"}). We then further separated the shRNAs into two groups: those that were toxic just after infection and those toxic after addition of Dox ([Figure 7B](#fig7){ref-type="fig"}, [Supplementary file 5](#supp5){ref-type="supplementary-material"}). In each ranked list, we could now assess whether the experimentally determined toxicity of shRNAs correlated with the *in silico* predicted TI. Remarkably, the highest enrichment of toxic shRNAs was found amongst those with higher TI for the subpool of shRNAs targeting the CD95L ORF followed by shRNAs in the subpool targeting the CD95 3\'UTR. To confirm the significance of this finding, we repeated the analysis 10,000 times by randomly assigning 8mers and their associated TIs to the two shRNA pools and again sorted the data from highest to lowest TI. The reported p-values were calculated based on these permutated datasets using Mann-Whitney U tests.

We noticed that survival genes tend to be more highly expressed than nonsurvival genes (data not shown). To address the question whether toxic si/shRNAs only target survival genes or all genes that are highly expressed, we recalculated the TI based on a set of 850 highly expressed and expression matched survival and nonsurvival genes ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). This alternative TI tracked slightly less well with the toxic shRNAs we identified, but the enrichment of toxic shRNAs towards the top of the list ranked according to the new TI was still statistically significant ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). This analysis demonstrates survival genes contain more seed matches for toxic shRNAs in their 3\'UTR than nonsurvival genes regardless of the expression level. This suggests, to a certain extent, it is possible to predict the experimental toxicity of shRNAs based on the *in silico* calculated TI.

Our data suggest DISE results from a sequence-specific off-target activity that depends on the presence of certain seed matches in the 3\'UTR of survival genes. Thus, DISE inducing RISC associated small RNAs behave in manner similar to miRNAs. This raised the question whether these seed matches have special properties. While we did not find a sequence motif that was present in all toxic si/shRNAs, we did find that sequence composition, specifically GC content, which has been reported to affect the specificity of shRNAs ([@bib22]; [@bib68]), correlated with the toxicity of shRNAs. When the GC content of the 6mer seed sequences of all underrepresented shRNAs detected in the shRNA screen across the CD95L ORF was plotted, we found a significant correlation between the GC content and higher toxicity (indicated by underrepresentation) ([Figure 7C and D](#fig7){ref-type="fig"}). This correlation was even more pronounced when plotting GC content versus the 6mer toxicity index ([Supplementary file 4](#supp4){ref-type="supplementary-material"}) ([Figure 7E](#fig7){ref-type="fig"}). While not an absolute requirement, higher GC content made shRNAs more toxic, consistent with reports demonstrating that shRNAs with high GC content in the seed region showed decreased on-target and increased off-target activity ([@bib22]; [@bib68]). In summary, our data suggest that si- and/or shRNAs with certain seed sequences are toxic to cancer cells by targeting critical survival genes through an RNAi mechanism independent of both Drosha and Dicer. Furthermore, the data suggest high miRNA content, presumably through competing for occupancy in the RISC, might render cells less sensitive to DISE.

Discussion {#s3}
==========

Most current uses of RNAi are aimed toward highly specific silencing with little OTE. In fact, OTEs represent one of the largest impediments to the use of RNAi in phenotypic screening applications. We now demonstrate DISE is a unique form of OTE that results in the simultaneous activation of multiple cell death pathways in cancer cells. The discovery that DISE involves loss of multiple survival genes now provides an explanation for the unique properties we described for this form of cell death, especially the observation that cancer cells have a hard time developing resistance to this cell death mechanism ([@bib26]; [@bib48]).

DISE represents a specific form of RNAi OTE {#s3-1}
-------------------------------------------

There are a number of rules that have been elucidated for designing si/shRNAs ([@bib8]) to avoid undesired effects such as OTE ([@bib52]), general toxicity due to the presence of toxic sequence motifs ([@bib17]; [@bib52]), poisoning/saturating of the RISC ([@bib20]), or evocation of an IFN response ([@bib43]). The following arguments and evidence support our prediction that DISE is a manifestation of a novel, functionally important, conserved mechanism of genome regulation, and not the result of one of the above-mentioned effects:

1.  The sheer number of toxic shRNAs embedded in CD95L or CD95. A number of genome-wide shRNA and siRNA lethality screens have revealed that 2--5% of shRNAs targeting human genes are toxic to cells. We recently reported in 12 independent arrayed shRNA lethality screens the identification of 651 genes out of about 18,000 targeted genes that are critical for the survival of 8 different cancer cell lines ([@bib26]). Many of the genes targeted by these shRNAs were actually established survival genes (as discussed in \[[@bib26]\]). That means that the number of shRNAs that are toxic due to a possible OTE or general toxicity would be expected to be very small. In contrast, we found that \>80% of the shRNAs and siRNAs that were designed to target either CD95 or CD95L exhibited toxicity in multiple cell lines. Consistent with our data analysis, a parallel genome-scale loss of function screen confirmed that the majority of the tested shRNAs derived from either CD95L and CD95 were toxic to a majority of the tested 216 cell lines when used as a pooled library ([@bib14]). These also included a number of hematopoietic cell lines suggesting that the DISE effect is not limited to solid cancers. Interestingly, in this study the authors did not consider the data on most of the CD95L and CD95 targeting shRNAs to be significant as they received a low consistency score. A high consistency score predicts the observed phenotype (cell death or growth reduction in this case) is caused by knocking down the targeted gene ([@bib62]). However, we have demonstrated here that the toxicity of an shRNA is solely dependent on its seed and the transcriptome of the treated cells. Therefore, the results of every shRNA should be considered individually as far as the DISE inducing effect is concerned.

2.  High concentrations of siRNAs can saturate the RISC, preventing the access of crucial endogenous miRNAs ([@bib33]). We have demonstrated that, in general, 5 nM of CD95L-derived siRNAs are sufficient to kill cancer cells. We have even seen very efficient cell death with as little as 1 nM of siRNA (see [Figure 2I](#fig2){ref-type="fig"} and [Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}). It is therefore unlikely we are poisoning the RISC. It has been reported that in siRNA overexpression experiments, changes in mRNA expression can be caused by blocked access of endogenous miRNAs to the RISC, such as the highly expressed miRNA family, let-7 ([@bib33]). However, we can exclude such an effect in our analysis, as there was no significant enrichment (or depletion) of the let-7 seed match motif (or that of any other miRNA) in our analyses (black lines in [Figure 5A](#fig5){ref-type="fig"}).

3.  No IFN response was observed. We have performed multiple RNA-Seq and gene array analyses of cells in which DISE was induced by multiple si/shRNAs targeting CD95 or CD95L. In none of these analyses did we detect an increase in any of the known IFN response genes ([@bib61]) (data not shown). In addition, we demonstrated the latest generation of Dicer optimized 27mer DsiRNAs that do not elicit an IFN response ([@bib34]) and the shRNAs expressed from within the cells shown to have low IFN triggering activity ([@bib59]) have the same toxic activities as the standard 21mer siRNAs (see [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} *and 1B*).

4.  Mutation of just one position destroys activity. A major argument against DISE toxicity being caused by overloading the RISC, an IFN response or the presence of known toxic sequences, lies in the analysis of the chimeras we generated between siL3 and a non-toxic scrambled oligonucleotide (see [Figure 3H](#fig3){ref-type="fig"}). This analysis demonstrated that the seed match positions of siL3 are critical for its toxicity. In fact, just replacing one nucleotide in a critical position in the center of the seed match almost completely abolished toxicity of the siRNA.

What are the requirements for an si/shRNA to induce DISE? {#s3-2}
---------------------------------------------------------

Our data provide strong evidence that the toxicity observed is a sequence-specific event caused by seed matches present in the targets of the toxic si/shRNAs rather than by a toxic motif enriched in all toxic si/shRNAs (i.e. the UGGC motif described before \[[@bib17]\]). We did find a correlation between the toxicity of shRNAs (both predicted by the TI and experimentally determined in the shRNA screen) and the GC content in their seed region. While this correlation was significant, it was not a requirement as some of the most toxic si- and shRNAs had a low 8mer seed GC content (shL3, 25%; shR6, 25%; siL3, 37.5%). Our data suggest that survival genes may contain different types of seed matches (based on base composition or sequence) when compared to nonsurvival genes. Such a distinction has indeed been described before ([@bib64]). In a study in *Drosophila*, it was determined that survival genes are depleted of seed matches targeted by highly expressed miRNAs. These authors concluded that evolution must have selected against the presence of seed matches for highly expressed miRNAs in the 3\'UTR of survival genes. It is therefore not surprising that a gene ontology (GO) analysis of all miRNA targets (the 'targets') in this study described these genes as being involved in development and differentiation ([@bib64]). In contrast, genes not targeted by miRNAs (the 'antitargets') grouped in GO clusters that were consistent with cell survival ([@bib64]). A similar phenomenon was also shown in mammalian cells; genes with fewer miRNA target sites, as predicted by Targetscan, contained distinct enriched GO terms from those enriched in genes with many predicted target sites. The genes with fewer sites were enriched in GO terms like ribosomal subunits and respiratory chain, whereas target-heavy genes were more enriched in regulatory-related GO terms ([@bib75]). It is possible the DISE-inducing si/shRNAs carry seed sequences that preferentially target seed matches present in the 3'UTRs of the 'anti-targets'. However, as our data on the miR-30 based shRNAs suggest, DISE-inducing shRNAs must be expressed at a certain level to be toxic.

DISE is caused by loading of the guide strand of toxic si/shRNAs into the RISC {#s3-3}
------------------------------------------------------------------------------

Part of our data was generated using a widely used first generation stem loop shRNA platform, the TRC library. The TRC shRNAs have recently been found to be prone to cause OTE. Gu *et al.* showed that the loop design of this system results in imprecise Dicer cleavage and, consequently, the production of different mature small-RNA species that increase passenger loading, one major source of OTE ([@bib21]). More recently, it was reported that most guide RNAs derived from the TRC hairpin were shifted by 4 nt 3\' of the expected 5\' start site ([@bib71]). While we did see a shift in processing of these stem loop shRNAs, we did not see such a high level of imprecision in the cleavage of our toxic shRNAs. In fact, 99.4% of the shR6 guide RNAs started at the same nucleotide position ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). The majority of the processing of both our pTIP and pLKO-based shRNAs was shifted by one nucleotide ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). This shift was consistent with the defined seed matches that were detected in the Sylamer analyses. In general, one major seed match was detected with one other minor species (this was less obvious for shL1, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Furthermore, all four Sylamer analyses only detected enrichments in the 3\'UTR of downregulated mRNAs that were consistent with only the guide strand targeting the mRNA and not the passenger strand. In all cases, including in cells transfected with the siRNA siL3, the primary enriched sequence motifs were either 7, or 8mers present in the 3\'UTR of the targeted mRNAs.

DISE has features of the RNAi OTE previously reported {#s3-4}
-----------------------------------------------------

Our data on DISE are consistent with a number of properties of RNAi OTE that have previously been reported. Similar to DISE, OTE-mediated silencing requires a 6/7nt seed sequence of complementarity ([@bib6]; [@bib30]; [@bib39]) and it targets mRNAs in the 3\'UTR ([@bib6]). Our data on shRNAs, siRNAs, and DsiRNAs suggest that DISE is not limited to one platform and requires sequence-specific targeting. This conclusion is also consistent with a previous report that suggested that sequence-dependent off-target transcript regulation is independent of the delivery method ([@bib30]). The authors found the same enrichment of 6mers and 7mers in 3\'UTRs of targeted mRNAs for siRNAs and shRNAs ([@bib30]).

The role of Dicer in DISE {#s3-5}
-------------------------

We previously reported that Dicer^Exo5-/-^ HCT116 cells (with deleted Exon 5) were at least as sensitive to induction of DISE (by either shL3 or shR6) than wt cells suggesting that Dicer deficient cells could be killed by DISE ([@bib26]). It has been reported that these Dicer deficient cells are hypomorphs ([@bib67]) and indeed, we detected low residual Dicer expression by western blotting ([@bib26]). We have now revisited this issue with HCT116 cells rendered completely deficient for Dicer using CRISPR/Cas9 gene editing ([@bib35]). The fact that these Dicer^-/-^ cells were now completely resistant to the toxic effects of shL3 or shR6 demonstrates the complete absence of Dicer protein and activity. Similar to the Drosha^-/-^ cells, in the absence of mature miRNAs, which seem to attenuate DISE, Dicer^-/-^ cells are hypersensitive to DISE induced by siRNAs.

Open questions regarding the relevance of DISE {#s3-6}
----------------------------------------------

We are proposing an entirely new concept of killing cancer cells that is based on the toxicity of CD95 and CD95L derived small RNAs. Naturally, there are many open questions such as:

1.  Is DISE part of an anti-cancer mechanism? We are proposing that DISE kills cancer cells in a way that they usually cannot escape from. We have not found a way to block cancer cells from dying by DISE. We provide strong evidence to suggest this is due to the simultaneous targeting of multiple survival genes that result in the activation of multiple cell death pathways. It will be difficult to prove cells are dying due to the preferential targeting of survival genes. It may never be possible to express multiple siRNA resistant survival genes at the same time at physiological levels to render cancer cells resistant to the action of countless small RNAs. This prediction alone makes DISE a promising new strategy to kill cancer cells.

2.  Does CD95L induce DISE *in vivo*? We recently found that overexpression of the CD95L ORF is toxic to cancer cells and that this kills cancer cells in a manner very similar to DISE induction (unpublished data). We and others have noticed upregulation of CD95L in multiple stress-related conditions such as treatment with chemotherapy (\[[@bib18]\] and data not shown). While the amount of CD95L RNA and the level of upregulation alone may not be enough to induce DISE, it could result from the combined expression of multiple RNAs that when generated kill cells by DISE. We view CD95L as just one of many RNAs that have this activity.

3.  Are there other genes in the human genome containing toxic seed sequences? We recently identified other genes in the genome that contain DISE-inducing shRNAs ([@bib50]). It is therefore possible that when cells are subjected to genotoxic or oncogenic stress that they generate numerous small RNAs that can be taken up by the RISC and in combination execute DISE. Hence, our analysis of CD95/CD95L will likely be applicable to other genes.

A model for why DISE preferentially kills cancer cells {#s3-7}
------------------------------------------------------

We interpret the hypersensitivity of both Drosha^-/-^ and Dicer^-/-^ cells to DISE in the following way: Most of the small RNAs in the cells that are loaded into the RISC are miRNAs. Using AGO pull-down experiments, we determined 98.4% of AGO- associated RNAs in HCT116 cells to be miRNAs (99.3% in HeyA8 cells, data not shown). It was recently reported that Drosha^-/-^ cells showed a reduction of miRNA content from roughly 70--80% to 5--6%, and Dicer^-/-^ cells showed a reduction down to 14--21% ([@bib35]). Since neither Drosha^-/-^ nor Dicer^-/-^ cells express reduced AGO2 protein levels (see inset in [Figure 3E](#fig3){ref-type="fig"}), it is reasonable to assume that their RISC can take up many more of the toxic DISE inducing RNAs than the RISC in wt cells explaining the super toxicity of both DISE inducing si/shRNAs and CD95L mRNAs in these cells.

We previously showed expression of either shL3 and shR6 induced DISE in immortalized normal ovarian fibroblasts much more efficiently than in matching nonimmortalized cells ([@bib26]), suggesting that this form of cell death preferentially affects transformed cells. Our data now provide an interesting model to explain the higher sensitivity of cancer cells to DISE when compared to normal cells. It is well documented that cancer cells in general have global downregulation of miRNAs when compared to normal tissues ([@bib41]). This might free up the RISC for DISE-inducing RNAs and would imply that miRNAs may protect normal cells from DISE.

Overall, our data allow us to predict that any small RNA with DISE-inducing RNAi activity that does not require Dicer processing can kill cancer cells regardless of Dicer or Drosha status. In fact, in an accompanying manuscript, we demonstrate that DISE can be triggered *in vivo* to treat ovarian cancer in mouse xenografts by delivering CD95L-derived siRNAs using nanoparticles ([@bib48]). No toxicity was observed in the treated mice. These data suggest that it might be possible to develop a novel form of cancer therapy based on the DISE OTE mechanism.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation                                                   Source or reference       Identifiers                                                               Additional information
  or resource                                                                                                                                                                                 
  ------------------------- ------------------------------------------------------------- ------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  Gene (Homo sapiens)       CD95L                                                         NA                        NM_000639                                                                 

  Gene (H. sapiens)         CD95                                                          NA                        NM_000043                                                                 

  Cell line (H. sapiens)    NB7                                                           PMID: 10802708            BRENDA Tissue and\                                                        Human neuroblastoma derived from\
                                                                                                                    Enzyme Source\                                                            autonomic ganglia; carries a deletion\
                                                                                                                    Ontology: BTO_0003439;\                                                   in both alleles of CASP8
                                                                                                                    RRID:[CVCL_8824](https://scicrunch.org/resolver/CVCL_8824)                

  Cell line (H. sapiens)    HeyA8                                                         PMID: 4016745;\           RRID: [CVCL_8878](https://scicrunch.org/resolver/CVCL_8878);\             Human high grade ovarian\
                                                                                          PMID: 25984343            RRID:[CVCL_8878](https://scicrunch.org/resolver/CVCL_8878)                serous adenocarcinoma; derived\
                                                                                                                                                                                              from parent Hey cells (RRID: [CVCL_0297](https://scicrunch.org/resolver/CVCL_0297))

  Cell line (H. sapiens)    HeyA8 ΔshL3                                                   this paper                NA                                                                        Pool of three HeyA8 cell clones with\
                                                                                                                                                                                              homozygous 41 nucleotide deletion\
                                                                                                                                                                                              of the shL3 target site\
                                                                                                                                                                                              (chr1:172,665,726--172,655,766; Human\
                                                                                                                                                                                              Dec. 2013 GRCh38/hg38 assembly)\
                                                                                                                                                                                              produced using CRISPR/Cas9 technology.

  Cell line (H. sapiens)    HeyA8 ΔsiL3                                                   this paper                NA                                                                        Pool of three HeyA8 cell clones with\
                                                                                                                                                                                              homozygous 64 nucleotide deletion of\
                                                                                                                                                                                              the siL3 target site\
                                                                                                                                                                                              (chr1:172,669,178--172,659,241; Human\
                                                                                                                                                                                              Dec. 2013 GRCh38/hg38 assembly)\
                                                                                                                                                                                              produced using CRISPR/Cas9 technology.

  Cell line (H. sapiens)    HeyA8 ΔshR6; shR6\                                            this paper                NA                                                                        HeyA8 cell clone \#11 with homozygous\
                            k.o. clone \#11                                                                                                                                                   227 nucleotide deletion of the shR6\
                                                                                                                                                                                              target site (chr10:89,008,920--89,009,146;\
                                                                                                                                                                                              Human Dec. 2013 GRCh38/hg38\
                                                                                                                                                                                              assembly) produced using\
                                                                                                                                                                                              CRISPR/Cas9 technology; verified\
                                                                                                                                                                                              homozygous CD95 protein knockout

  Cell line (H. sapiens)    HeyA8 shR6 k.o.\                                              this paper                NA                                                                        HeyA8 cell clone \#1 with a small deletion\
                            clone \#1                                                                                                                                                         and the 227 nucleotide deletion of the\
                                                                                                                                                                                              shR6 target site and an insertion of the\
                                                                                                                                                                                              pMJ920 plasmid fragment in CD95\
                                                                                                                                                                                              produced using CRISPR/Cas9\
                                                                                                                                                                                              technology; verified homozygous\
                                                                                                                                                                                              CD95 protein knockout

  Cell line (H. sapiens)    HeyA8 shR6 k.o.\                                              this paper                NA                                                                        HeyA8 cell clone \#2 with a 227\
                            clone \#2                                                                                                                                                         nucleotide deletion of the shR6\
                                                                                                                                                                                              target site (chr10:89,008,920--89,009,146;\
                                                                                                                                                                                              Human Dec. 2013 GRCh38/hg38 assembly)\
                                                                                                                                                                                              in one allele and an insertion of the\
                                                                                                                                                                                              pSCB plasmid fragment in the other\
                                                                                                                                                                                              in CD95 produced using\
                                                                                                                                                                                              CRISPR/Cas9 technology; verified\
                                                                                                                                                                                              homozygous CD695 protein knockout

  Cell line (H. sapiens)    MCF-7                                                         ATCC                      ATCC: HTB-22;\                                                            Human adenocarcinoma of the mammary\
                                                                                                                    RRID:[CVCL_0031](https://scicrunch.org/resolver/CVCL_0031)                gland, breast; derived from metastatic\
                                                                                                                                                                                              site: pleural effusion

  Cell line (H. sapiens)    HCT116                                                        Korean Collection for\    KCTC: cat\#HC19023;\                                                      Human colorectal carcinoma
                                                                                          Type Cultures (KCTC)      ATCC: CCL_247;\                                                           
                                                                                                                    RRID:[CVCL_0291](https://scicrunch.org/resolver/CVCL_0291)                

  Cell line (H. sapiens)    Drosha^-/-^; Drosha^-/-^\                                     Korean Collection for\    KCTC: cat\#HC19020                                                        HCT116 clone \#40 with homozygous\
                            clone \#40                                                    Type Cultures (KCTC);\                                                                              protein knockout of Drosha; knockout\
                                                                                          PMID: 26976605                                                                                      achieved using CRISPR/Cas9 which\
                                                                                                                                                                                              resulted in a single nucleotide insertion\
                                                                                                                                                                                              in one allele and a 26 nuceotide\
                                                                                                                                                                                              deletion in the other

  Cell line (H. sapiens)    Dicer^-/-^; Dicer^-/-^\                                       Korean Collection for\    KCTC: cat\#HC19023                                                        HCT116 clone \#43 with homozygous\
                            clone \#43                                                    Type Cultures (KCTC);\                                                                              protein knockout of Dicer; knockout\
                                                                                          PMID: 26976606                                                                                      achieved using CRISPR/Cas9 which\
                                                                                                                                                                                              resulted in a three nucleotide\
                                                                                                                                                                                              insertion and 14 nucleotide deltion\
                                                                                                                                                                                              in one allele and a 35 nuceotide\
                                                                                                                                                                                              deletion in the other

  Cell line (H. sapiens)    Dicer^-/-^; Dicer^-/-^\                                       Korean Collection for\    KCTC: cat\#HC19024                                                        HCT116 clone \#45 with homozygous\
                            clone \#45                                                    Type Cultures (KCTC);\                                                                              protein knockout of Dicer; knockout\
                                                                                          PMID: 26976607                                                                                      achieved using CRISPR/Cas9 which\
                                                                                                                                                                                              resulted in a 53 nucleotide deltion\
                                                                                                                                                                                              in one allele and a 28 nuceotide\
                                                                                                                                                                                              deletion in the other

  Cell line (H. sapiens)    293T                                                          ATCC                      ATCC: CRL-3216;\                                                          Derived from HEK293 cells\
                                                                                                                    RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)                (ATCC: CRL-1573); express large T\
                                                                                                                                                                                              antigen; used for packaging viruses

  Cell line (H. sapiens)    293T ΔshL3                                                    this paper                NA                                                                        Pool of three 293T cell clones with\
                                                                                                                                                                                              homozygous 41 nucleotide deletion\
                                                                                                                                                                                              of the shL3 target site\
                                                                                                                                                                                              (chr1:172,665,726--172,655,766;\
                                                                                                                                                                                              Human Dec. 2013 GRCh38/hg38\
                                                                                                                                                                                              assembly) produced using\
                                                                                                                                                                                              CRISPR/Cas9 technology.

  Cell line (H. sapiens)    Phoenix-AMPHO                                                 ATCC                      ATCC: CRL-3213;\                                                          Second generation retrovirus\
                                                                                                                    RRID:[CVCL_H716](https://scicrunch.org/resolver/CVCL_H716)                producer cell line

  Antibody                  anti-β-actin antibody\                                        Santa Cruz                Santa Cruz:\                                                              1:2000; for western blot;\
                            (mouse monoclonal)                                                                      cat\#sc-47778;\                                                           primary Ab
                                                                                                                    RRID:[AB_626632](https://scicrunch.org/resolver/AB_626632)                

  Antibody                  anti-human CD95L\                                             BD Biosciences            BD Biosciences:\                                                          1:500; for western blot;\
                            (Mouse IgG1\                                                                            cat\#556387;\                                                             primary Ab
                            monoclonal)                                                                             RRID:[AB_396402](https://scicrunch.org/resolver/AB_396402)                

  Antibody                  anti-human CD95\                                              Santa Cruz                Santa Cruz:\                                                              1:1000; for western blot;\
                            (rabbit polyclonal)                                                                     cat\#sc-715;\                                                             primary Ab
                                                                                                                    RRID:[AB_2100386](https://scicrunch.org/resolver/AB_2100386)              

  Antibody                  anti-human AGO2\                                              Abcam                     Abcam: cat\#AB186733;\                                                    1:2000; for western blot;\
                            (rabbit monoclonal)                                                                     RRID:[AB_2713978](https://scicrunch.org/resolver/AB_2713978)              primary Ab

  Antibody                  anti-human Drosha\                                            Cell Signaling            Cell Signaling:\                                                          1:1000; for western blot;\
                            (rabbit monoclonal)                                                                     cat\#3364;\                                                               primary Ab
                                                                                                                    RRID:[AB_2238644](https://scicrunch.org/resolver/AB_2238644)              

  Antibody                  anti-human Dicer\                                             Cell Signaling            Cell Signaling:\                                                          1:1000; for western blot;\
                            (rabbit polyclonal)                                                                     cat\#3363;\                                                               primary Ab
                                                                                                                    RRID:[AB_2093073](https://scicrunch.org/resolver/AB_2093073)              

  Antibody                  Goat anti-rabbit,\                                            Southern Biotech          Southern Biotech:\                                                        1:5000; for western blot;\
                            IgG-HRP                                                                                 cat\#SB-4030--05;\                                                        secondary Ab
                                                                                                                    RRID:[AB_2687483](https://scicrunch.org/resolver/AB_2687483)              

  Antibody                  Goat anti-rabbit,\                                            Cell Signaling            Cell Signaling:\                                                          1:2000; for western blot;\
                            IgG-HRP                                                                                 cat\#7074; RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)   secondary Ab

  Antibody                  Goat anti-mouse;\                                             Southern Biotech          Southern BioTech:\                                                        1:5000; for western blot;\
                            IgG1-HRP                                                                                cat\#1070--05;\                                                           secondary Ab
                                                                                                                    RRID:[AB_2650509](https://scicrunch.org/resolver/AB_2650509)              

  Isotype control           FITC-mouse IgG1,\                                             BD Biosciences            BD Biosciences:\                                                          4 uL used for 1 × 10\^6 cells;\
                            κ isotype control                                                                       cat\#551954;\                                                             for flow cytometry
                                                                                                                    RRID:[AB_394297](https://scicrunch.org/resolver/AB_394297)                

  Antibody                  FITC-mouse\                                                   BD Biosciences            BD Biosciences:\                                                          4 uL used for 1 × 10\^6 cells;\
                            anti-Human CD95                                                                         cat\#556640;\                                                             for flow cytometry
                                                                                                                    RRID:[AB_396506](https://scicrunch.org/resolver/AB_396506)                

  Recombinant protein\      sCD95L (S2)                                                   PMID: 14504390            NA                                                                        Soluble form of human CD95L\
  reagent                                                                                                                                                                                     (amino acids 137--281);\
                                                                                                                                                                                              recombinant protein

  Recombinant protein\      LzCD95L                                                       PMID: 14504390            NA                                                                        Leucine zipper tagged CD95L;\
  reagent                                                                                                                                                                                     recombinant protein

  Chemical compound         propidium iodide                                              Sigma-Aldrich             Sigma-Aldrich:\                                                           Used for subG1 flow cytometry analysis
                                                                                                                    cat\#P4864                                                                

  Chemical compound         puromycin                                                     Sigma-Aldrich             Sigma-Aldrich:\                                                           Used for selection of cells expressing\
                                                                                                                    cat\#P9620                                                                puromycin resistance cassettes

  Chemical compound         G418                                                          Affymetrix                Affymetrix:\                                                              Used for selection of cells\
                                                                                                                    cat\#11379                                                                expressing G418 resistance cassette

  Recombinant DNA\          venus-CD95L\                                                  this paper                NA                                                                        Modified CD510B-1 lentiviral vector\
  reagent                   sensor (plasmid)                                                                                                                                                  (PMID: 25366259) was used as backbone;\
                                                                                                                                                                                              vector expresses a venus-human\
                                                                                                                                                                                              CD95L conjugate mRNA that can be\
                                                                                                                                                                                              used to monitor RNAi activity of\
                                                                                                                                                                                              si/shRNAs targeting CD95L using\
                                                                                                                                                                                              venus fluorescence.

  Recombinant DNA\          venus-CD95\                                                   this paper                NA                                                                        Modified CD510B-1 lentiviral vector\
  reagent                   sensor (plasmid)                                                                                                                                                  (PMID: 25366259) was used as backbone;\
                                                                                                                                                                                              vector expresses a venus-human CD95\
                                                                                                                                                                                              conjugate mRNA that can be used\
                                                                                                                                                                                              to monitor RNAi activity of\
                                                                                                                                                                                              si/shRNAs targeting CD95\
                                                                                                                                                                                              using venus fluorescence.

  Recombinant DNA\          pLenti-GIII-CMV-\                                             ABM Inc                   NA                                                                        pLenti control empty lentiviral vector;\
  reagent                   RFP-2A-Puro\                                                                                                                                                      carries an RFP-2a-puromycin\
                            vector; pLenti                                                                                                                                                    resistance cassette

  Recombinant DNA\          pLNCX2                                                        Clontech                  Clontech:\                                                                pLNCX2 control empty\
  reagent                                                                                                           cat\#631503                                                               retroviral vector;\
                                                                                                                                                                                              carries a neomycin\
                                                                                                                                                                                              resistance cassette

  Recombinant DNA\          pTIP                                                          PMID: 24656822            NA                                                                        Lentivirus used for doxycycline-\
  reagent                                                                                                                                                                                     induced expression of shRNAs;\
                                                                                                                                                                                              contains puromycin resistance\
                                                                                                                                                                                              cassette; modified from the\
                                                                                                                                                                                              original backbone which\
                                                                                                                                                                                              contained a GFP cassette instead\
                                                                                                                                                                                              of a puromycin cassette\
                                                                                                                                                                                              (PMID: 17311008); original\
                                                                                                                                                                                              backbone from the Rossi lab.

  Recombinant DNA\          pLenti-CD95L-WT                                               this paper                NA                                                                        pLenti-GIII-CMV-RFP-2A-Puro vector\
  reagent                                                                                                                                                                                     that expresses human wild type\
                                                                                                                                                                                              CD95L cDNA (NM_000639.2);\
                                                                                                                                                                                              used to express wt human\
                                                                                                                                                                                              CD95L upon infection\
                                                                                                                                                                                              with lentiviral particles

  Recombinant DNA\          pLenti-CD95L-\                                                this paper                NA                                                                        pLenti-GIII-CMV-RFP-2A-Puro vector\
  reagent                   L1MUT                                                                                                                                                             that expresses human CD95L\
                                                                                                                                                                                              cDNA (NM_000639.2) with 8\
                                                                                                                                                                                              silentmutations overlapping\
                                                                                                                                                                                              the shL1 target site\
                                                                                                                                                                                              (GCATCATCTTTGGAGAAGCAA\
                                                                                                                                                                                              - \> GCCTCGTCCCTAGAAAAACAG); used\
                                                                                                                                                                                              to express shL1-resistant human\
                                                                                                                                                                                              CD95L upon infection\
                                                                                                                                                                                              with lentiviral particles

  Recombinant DNA\          pLenti-CD95L-\                                                this paper                NA                                                                        pLenti-GIII-CMV-RFP-2A-Puro vector\
  reagent                   L3MUT                                                                                                                                                             that expresses human CD95L\
                                                                                                                                                                                              cDNA (NM_000639.2) with 8 silent\
                                                                                                                                                                                              mutations overlapping the shL3\
                                                                                                                                                                                              target site\
                                                                                                                                                                                              (ACTGGGCTGTACTTTGTATAT\
                                                                                                                                                                                              - \> ACCGGATTATATTTCGTGTAC);\
                                                                                                                                                                                              used to express shL3-resistant\
                                                                                                                                                                                              human CD95L upon infection\
                                                                                                                                                                                              with lentiviral particles

  Recombinant DNA\          pLNCX2-CD95-WT                                                this paper                NA                                                                        pLNCX2 vector that expresses\
  reagent                                                                                                                                                                                     human CD95 cDNA (BC012479.1);\
                                                                                                                                                                                              used to express wild type CD95\
                                                                                                                                                                                              upon infection with lentiviral particles

  Recombinant DNA\          pLNCX2-CD95-R6MUT                                             this paper                NA                                                                        pLNCX2 vector that expresses mutant\
  reagent                                                                                                                                                                                     human CD95 cDNA (BC012479.1) which\
                                                                                                                                                                                              contains 8 silent mutations\
                                                                                                                                                                                              overlapping the shR6 site\
                                                                                                                                                                                              (GTGTCGCTGTAAACCAAACTT\
                                                                                                                                                                                              - \> ATGTCGCTGCAAGCCCAATTT);\
                                                                                                                                                                                              used to express shR6-resistant\
                                                                                                                                                                                              CD95 upon infection with\
                                                                                                                                                                                              lentiviral particles

  Transfected construct     gRNA scaffold                                                 PMID: 23287722            IDT: synthesized\                                                         455 nucleotide CRISPR/Cas9\
                                                                                                                    as gene block                                                             gRNA scaffold synthesized as a\
                                                                                                                                                                                              gene block; contains promoter,\
                                                                                                                                                                                              gRNA scaffold, target sequence,\
                                                                                                                                                                                              and termination sequence; scaffold\
                                                                                                                                                                                              transcribes gRNAs that target Cas9\
                                                                                                                                                                                              endonuclease to cut at target sites;\
                                                                                                                                                                                              target sequences consist of 19\
                                                                                                                                                                                              nucleotides that are complementary to\
                                                                                                                                                                                              the target site of choice; co-transfected\
                                                                                                                                                                                              with Cas9 to catalyze cleavage.

  Transfected construct     pMJ920 Cas9 plasmid                                           Addgene;\                 Addgene: cat\#42234                                                       Plasmid that expresses a human\
                                                                                          PMID: 23386978                                                                                      codon-optimized Cas9 tagged with\
                                                                                                                                                                                              GFP and HA; used to express Cas9 for\
                                                                                                                                                                                              CRISPR-mediated deletions.

  Chemical compound         Lipofectamine 2000                                            ThermoFisher Scientific   ThermoFisher Scientific:\                                                 Transfection reagent
                                                                                                                    cat\#11668019                                                             

  Chemical compound         Lipofectamine RNAiMAX                                         ThermoFisher Scientific   ThermoFisher Scientific:\                                                 Transfection reagent; used for\
                                                                                                                    cat\#13778150                                                             transfection of small RNAs such as siRNAs

  Commercial assay or kit   StrataClone Blunt\                                            Agilent Technologies      Agilent Technologies:\                                                    Used to blunt-end clone the gRNA\
                            PCR Cloning Kit                                                                         cat\#240207                                                               scaffolds into the pSC-B plasmid

  Commercial assay or kit   High-Capacity cDNA\                                           Applied Biosystems        4368814                                                                   
                            reverse transcription kit                                                                                                                                         

  Array cards preloaded\    384-well TLDA cards                                           Applied Biosystems        43422489                                                                  
  with primers                                                                                                                                                                                

  Commercial assay kit      Taqman Gene\                                                  ThermoFisher Scientific   4369016                                                                   
                            expression master mix                                                                                                                                             

  Sequence-based reagent    shL3 flanking Fr primer                                       IDT                       IDT: custom DNA oligo                                                     Fr primer that flanks shL3 site;\
                                                                                                                                                                                              used to detect 41 nt shL3 deletion;\
                                                                                                                                                                                              5'-TCTGGAATGGGAAGACACCT-3'

  Sequence-based reagent    shL3 flanking Rev primer                                      IDT                       IDT: custom DNA oligo                                                     Rev primer that flanks shL3 site;\
                                                                                                                                                                                              used to detect 41 nt shL3 deletion;\
                                                                                                                                                                                              5'-CCTCCATCATCACCAGATCC-3'

  Sequence-based reagent    shL3 internal Rev primer                                      IDT                       IDT: custom DNA oligo                                                     Rev primer that overlaps with the shL3 site;\
                                                                                                                                                                                              used to detect 41 nt shL3 deletion;\
                                                                                                                                                                                              5'-ATATACAAAGTACAGCCCAGT-3'

  Sequence-based reagent    shR6 flanking Fr primer                                       IDT                       IDT: custom DNA oligo                                                     Fr primer that flanks shR6 site;\
                                                                                                                                                                                              used to detect 227 nt shR6 deletion;\
                                                                                                                                                                                              5'-GGTGTCATGCTGTGACTGTTG-3'

  Sequence-based reagent    shR6 flanking Rev primer                                      IDT                       IDT: custom DNA oligo                                                     Rev primer that flanks shR6 site;\
                                                                                                                                                                                              used to detect 227 nt shR6 deletion;\
                                                                                                                                                                                              5'-TTTAGCTTAAGTGGCCAGCAA-3'

  Sequence-based reagent    shR6 internal Rev primer                                      IDT                       IDT: custom DNA oligo                                                     Rev primer that overlaps with the shR6 site;\
                                                                                                                                                                                              used to detect 227 nt shR6 deletion;\
                                                                                                                                                                                              5'-AAGTTGGTTTACATCTGCAC-3'

  Sequence-based reagent    siL3 flanking Fr primer                                       IDT                       IDT: custom DNA oligo                                                     Fr primer that flanks siL3 site;\
                                                                                                                                                                                              used to detect 64 nt siL3 deletion;\
                                                                                                                                                                                              5'-CTTGAGCAGTCAGCAACAGG-3'

  Sequence-based reagent    siL3 flanking Rev primer                                      IDT                       IDT: custom DNA oligo                                                     Rev primer that flanks siL3 site;\
                                                                                                                                                                                              used to detect 64 nt siL3 deletion;\
                                                                                                                                                                                              5'-CAGAGGTTGGACAGGGAAGA-3'

  Sequence-based reagent    siL3 internal Rev primer                                      IDT                       IDT: custom DNA oligo                                                     Rev primer that is internal to the siL3 site;\
                                                                                                                                                                                              used to detect 64 nt siL3 deletion;\
                                                                                                                                                                                              5'-ATATGGGTAATTGAAGGGCTG-3'.

  Sequence-based reagent    siScr                                                         IDT; Dharmacon            Dharmacon\                                                                sense: UGGUUUACAUGUUGUGUGA
                                                                                                                    \#D-001810-02-05                                                          

  Sequence-based reagent    siL1                                                          Dharmacon                 L-011130-00-0005                                                          sense: UACCAGUGCUGAUCAUUUA

  Sequence-based reagent    siL1                                                          IDT                       customer synthesis                                                        sense: UACCAGUGCUGAUCAUUUA

  Sequence-based reagent    siL2                                                          IDT                       customer synthesis                                                        sense: CAACGUAUCUGAGCUCUCU

  Sequence-based reagent    siL3                                                          IDT                       customer synthesis                                                        sense: GCCCUUCAAUUACCCAUAU

  Sequence-based reagent    siL3MUT                                                       IDT                       IDT \#51-01-14-03                                                         sense: GGACUUCAACUAGACAUCU

  Sequence-based reagent    siL4                                                          IDT                       customer synthesis                                                        sense: GGAAAGUGGCCCAUUUAAC

  Sequence-based reagent    shL3 =\> siL3                                                 IDT                       customer synthesis                                                        sense: GACUGGGCUGU\
                                                                                                                                                                                              ACUUUGUAdTdA\
                                                                                                                                                                                              antisense: UACAAAGUACA\
                                                                                                                                                                                              GCCCAGUUdTdT

  Sequence-based reagent    shR6 =\> siR6                                                 IDT                       customer synthesis                                                        sense: GGGUGCAGAU\
                                                                                                                                                                                              GUAAACCAAAdCdT;\
                                                                                                                                                                                              antisense: UUUGGUUUACA\
                                                                                                                                                                                              UCUGCACUUdTdT

  Sequence-based reagent    Dsi-13.2                                                      IDT                       customer synthesis                                                        sense: AUCUU ACCAGUGC\
                                                                                                                                                                                              UGAUCAUUUAdTdA

  Sequence-based reagent    Dsi-13.3                                                      IDT                       customer synthesis                                                        sense: AAAGUAUACUU\
                                                                                                                                                                                              CCGGGGUCAAUCdTdT

  Sequence-based reagent    Dsi-13.9                                                      IDT                       customer synthesis                                                        sense: CUUCCGGGG\
                                                                                                                                                                                              UCAAUCUUGCAACAdAdC

  Sequence-based reagent    Dsi-13.x                                                      IDT                       customer synthesis                                                        sense: CAGGACUGAGAAG\
                                                                                                                                                                                              AAGUAAAACCdGdT

  Sequence-based reagent    DsiL3                                                         IDT                       customer synthesis                                                        sense: CAGCCCUUCAAU\
                                                                                                                                                                                              UACCCAUAUCCdCdC

  Sequence-based reagent    siScr pool                                                    Dharmacon                 D-001810--10                                                              

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-014208--02                                                              
                            targeting NUCKS1                                                                                                                                                  

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-012212--00                                                              
                            targeting CAPZA1                                                                                                                                                  

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-018339--00                                                              
                            targeting CCT3                                                                                                                                                    

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-013615--00                                                              
                            targeting FSTL1                                                                                                                                                   

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-011548--00                                                              
                            targeting FUBP1                                                                                                                                                   

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-017242--00                                                              
                            targeting GNB1                                                                                                                                                    

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-014597--01                                                              
                            targeting NAA50                                                                                                                                                   

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-020893--01                                                              
                            targeting PRELID3B                                                                                                                                                

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-019719--02                                                              
                            targeting SNRPE                                                                                                                                                   

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-003941--00                                                              
                            targeting TFRC                                                                                                                                                    

  Sequence-based reagent    smartpool siRNA\                                              Dharmacon                 L-006630--00                                                              
                            targeting HIST1H1C                                                                                                                                                

  Sequence based reagent\   GAPDH primer                                                  Thermofisher Scientific   Hs00266705_g1                                                             
  (human)                                                                                                                                                                                     

  Sequence based reagent\   CD95 primer                                                   Thermofisher Scientific   custom probe                                                              Fr primer: GGCTAACCCC\
  (human)                                                                                                                                                                                     ACTCTATGAATCAAT\
                                                                                                                                                                                              Rev primer: GGCCTGCCT\
                                                                                                                                                                                              GTTCAGTAACT\
                                                                                                                                                                                              Probe: CCTT\
                                                                                                                                                                                              TTGCTGAAATATC

  Sequence based reagent\   CD95 primer\                                                  Thermofisher Scientific   Hs00163653_m1                                                             
  (human)                   ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"})                                                                                                       

  Sequence based reagent\   CD95L primers                                                 Thermofisher Scientific   Hs00181226_g1;\                                                           
  (human)                                                                                                           Hs00181225_m1                                                             

  Sequence based reagent\   shL3 target\                                                  Thermofisher Scientific   custom probe                                                              Fr primer: *GGTGGCC*\
  (human)                   site in CD95L                                                                                                                                                     *TTGTGATCAATGAAA*\
                                                                                                                                                                                              Rev primer: *GCAAGA*\
                                                                                                                                                                                              *TTGACCCCGGAAGTATA*\
                                                                                                                                                                                              Probe: *CTG*\
                                                                                                                                                                                              *GGCTGTACTTTGTATATT*

  Sequence based reagent\   downstream of shL3 site                                       Thermofisher Scientific   custom probe                                                              Fr primer: *CCCC*\
  (human)                                                                                                                                                                                     *AGGATCTGGTGATGATG*\
                                                                                                                                                                                              Rev primer: *ACTG*\
                                                                                                                                                                                              *CCCCCAGGTAGCT*\
                                                                                                                                                                                              Probe: *CCCAC*\
                                                                                                                                                                                              *ATCTGCCCAGTAGT*

  Sequence based reagent\   GAPDH primer\                                                 Thermofisher Scientific   Hs99999905_m1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   ATP13A3 primer\                                               Thermofisher Scientific   Hs00225950_m1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   CAPZA1 primer\                                                Thermofisher Scientific   Hs00855355_g1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   CCT3 primer\                                                  Thermofisher Scientific   Hs00195623_m1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   FSTL1 primer\                                                 Thermofisher Scientific   Hs00907496_m1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   FUPB1 primer (\                                               Thermofisher Scientific   Hs00900762_m1                                                             
  (human)                   TLDA card)                                                                                                                                                        

  Sequence based reagent\   GNB1 primer\                                                  Thermofisher Scientific   Hs00929799_m1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   HIST1H1C\                                                     Thermofisher Scientific   Hs00271185_s1                                                             
  (human)                   primer (TLDA card)                                                                                                                                                

  Sequence based reagent\   NAA50 primer\                                                 Thermofisher Scientific   Hs00363889_m1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   NUCKS1 primer\                                                Thermofisher Scientific   Hs01068059_g1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   PRELID3B primer\                                              Thermofisher Scientific   Hs00429845_m1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   SNRPE primer\                                                 Thermofisher Scientific   Hs01635040_s1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Sequence based reagent\   TFRC primer\                                                  Thermofisher Scientific   Hs00951083_m1                                                             
  (human)                   (TLDA card)                                                                                                                                                       

  Software                  Stata 14                                                      Stata                                                                                               RRID:[SCR_012763](https://scicrunch.org/resolver/SCR_012763)

  Software                  Rstudio (R3.3.1)                                              Rstudio                                                                                             RRID:[SCR_000432](https://scicrunch.org/resolver/SCR_000432)

  sequence based reagent    shScr                                                         Sigma                     SHC002V                                                                   Non-targeting shRNA\
                                                                                                                                                                                              control transduction particles

  sequence based reagent\   shL1                                                          Sigma                     TRCN0000058998                                                            GCATCATCTTTGGAGAAGCAA
  (human)                                                                                                                                                                                     

  sequence based reagent\   shL2                                                          Sigma                     TRCN0000058999                                                            CCCATTTAACAGGCAAGTCCA
  (human)                                                                                                                                                                                     

  sequence based reagent\   shL3                                                          Sigma                     TRCN0000059000                                                            ACTGGGCTGTACTTTGTATAT
  (human)                                                                                                                                                                                     

  sequence based reagent\   shL4                                                          Sigma                     TRCN0000059001                                                            GCAGTGTTCAATCTTACCAGT
  (human)                                                                                                                                                                                     

  sequence based reagent\   shL5                                                          Sigma                     TRCN0000059002                                                            CTGTGTCTCCTTGTGATGTTT
  (human)                                                                                                                                                                                     

  sequence based reagent\   shL6                                                          Sigma                     TRCN0000372231                                                            TGAGCTCTCTCTGGTCAATTT
  (human)                                                                                                                                                                                     

  sequence based reagent\   shL2\'                                                        Sigma                     TRCN0000372232                                                            TAGCTCCTCAACTCACCTAAT
  (human)                                                                                                                                                                                     

  sequence based reagent\   shL5\'                                                        Sigma                     TRCN0000372175                                                            GACTAGAGGCTTGCATAATAA
  (human)                                                                                                                                                                                     

  sequence based reagent\   shR2                                                          Sigma                     TRCN0000218492                                                            CTATCATCCTCAAGGACATTA
  (human)                                                                                                                                                                                     

  sequence based reagent\   shR5                                                          Sigma                     TRCN0000038695                                                            GTTGCTAGATTATCGTCCAAA
  (human)                                                                                                                                                                                     

  sequence based reagent\   shR6                                                          Sigma                     TRCN0000038696                                                            GTGCAGATGTAAACCAAACTT
  (human)                                                                                                                                                                                     

  sequence based reagent\   shR7                                                          Sigma                     TRCN0000038697                                                            CCTGAAACAGTGGCAATAAAT
  (human)                                                                                                                                                                                     

  sequence based reagent\   shR8                                                          Sigma                     TRCN0000038698                                                            GCAAAGAGGAAGGATCCAGAT
  (human)                                                                                                                                                                                     

  sequence based reagent\   shR27\'                                                       Sigma                     TRCN0000265627                                                            TTTTACTGGGTACATTTTATC
  (human)                                                                                                                                                                                     

  sequence based reagent\   shR7\'                                                        Sigma                     TRCN0000255407                                                            TTAAATTATAATGTTTGACTA
  (human)                                                                                                                                                                                     

  sequence based reagent\   shR8\'                                                        Sigma                     TRCN0000255408                                                            ATATCTTTGAAAGTTTGTATT
  (human)                                                                                                                                                                                     

  sequence based reagent\   shR6\'                                                        Sigma                     TRCN0000255406                                                            CCCTTGTGTTTGGAATTATAA
  (human)                                                                                                                                                                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reagents and antibodies {#s4-1}
-----------------------

Primary antibodies for Western blot: anti-β-actin antibody (Santa Cruz \#sc-47778, RRID:[AB_626632](https://scicrunch.org/resolver/AB_626632)), anti-human CD95L (BD Biosciences \#556387, RRID:[AB_396402](https://scicrunch.org/resolver/AB_396402)), and anti-human CD95 (Santa Cruz \#sc-715, RRID:[AB_2100386](https://scicrunch.org/resolver/AB_2100386)), anti-human AGO2 (Abcam \#AB186733, RRID:[AB_2713978](https://scicrunch.org/resolver/AB_2713978)), anti-human Drosha (Cell Signaling \#3364, RRID:[AB_2238644](https://scicrunch.org/resolver/AB_2238644)), and anti-Dicer (Cell Signaling \#3363, RRID:[AB_2093073](https://scicrunch.org/resolver/AB_2093073)). Secondary antibodies for Western blot: Goat anti-rabbit; IgG-HRP (Southern Biotech \#SB-4030--05, RRID:[AB_2687483](https://scicrunch.org/resolver/AB_2687483) and Cell Signaling \#7074, RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)) and Goat anti-mouse; IgG1-HRP; (Southern BioTech \#1070--05, RRID:[AB_2650509](https://scicrunch.org/resolver/AB_2650509)). Conjugated antibody isotype control for CD95 surface staining were FITC-mouse anti-human CD95 (BD Biosciences \#556640, RRID:[AB_396506](https://scicrunch.org/resolver/AB_396506)) and FITC-mouse IgG1, ĸ isotype control (BD Biosciences \#551954, RRID:[AB_394297](https://scicrunch.org/resolver/AB_394297)). Recombinant soluble S2 CD95L and leucine-zipper tagged (Lz)CD95L were described before ([@bib1]). Reagents used: propidium iodide (Sigma-Aldrich \#P4864), puromycin (Sigma-Aldrich \#P9620), G418 (Affymetrix \#11379), doxycycline (Dox) (Sigma-Aldrich \#9891), Lipofectamine 2000 (ThermoFisher Scientific \#11668027), and Lipofectamine RNAiMAX (ThermoFisher Scientific \#13778150).

Cell lines {#s4-2}
----------

The ovarian cancer cell line HeyA8 (RRID:[CVCL_8878](https://scicrunch.org/resolver/CVCL_8878)), the neuroblastoma cell line NB7 (RRID:[CVCL_8824](https://scicrunch.org/resolver/CVCL_8824)), and the breast cancer cell line MCF-7 (RRID:[CVCL_0031](https://scicrunch.org/resolver/CVCL_0031)) were grown in RPMI 1640 medium (Cellgro \#10--040 CM), 10% heat-inactivated FBS (Sigma-Aldrich), 1% L-glutamine (Mediatech Inc), and 1% penicillin/streptomycin (Mediatech Inc). The human embryonic kidney cell line 293T (RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)) and Phoenix AMPHO (RRID:[CVCL_H716](https://scicrunch.org/resolver/CVCL_H716)) cells were cultured in DMEM (Cellgro \#10--013 CM), 10% heat-inactivated FBS, 1% L-Glutamine, and 1% penicillin/streptomycin.

HCT116 Drosha**^-/-^** and Dicer**^-/-^** cells were generated by Narry Kim ([@bib35]). HCT116 parental (cat\#HC19023, RRID:[CVCL_0291](https://scicrunch.org/resolver/CVCL_0291)), a Drosha^-/-^ clone (clone \#40, cat\#HC19020) and two Dicer^-/-^ clones (clone \#43, cat\#HC19023 and clone \#45, cat\#HC19024) were purchased from Korean Collection for Type Cultures (KCTC). All HCT116 cells were cultured in McCoy's medium (ATCC, cat\#30--2007), 10% heat-inactivated FBS, 1% L-Glutamine, and 1% penicillin/streptomycin. All cell lines were authenticated using STR profiling and tested monthly for mycoplasm using PlasmoTest (Invitrogen).

All lentiviruses were generated in 293T cells using pCMV-dR8.9 and pMD.G packaging plasmids. Retroviruses were generated in Phoenix AMPHO cells using the VSVg packaging plasmid.

NB7 cells overexpressing wild type and mutant CD95L cDNAs used in [Figure 1C and D](#fig1){ref-type="fig"} were generated by infecting cells seeded at 50,000 to 100,000 cells per well on a 6-well plate with empty pLenti, pLenti-CD95L-WT, pLenti-CD95L-L1MUT, and pLenti-CD95L-L3MUT (described below) with 8 μg/ml polybrene. Selection was done with 3 μg/ml puromycin for at least 48 hr.

MCF-7 cells overexpressing CD95 cDNAs used in [Figure 1F](#fig1){ref-type="fig"} were generated by seeding cells at 50,000 per well in a 6-well plate followed by infection with pLNCX2-CD95 or pLNCX2-CD95R6MUT (described below) in the presence of 8 μg/ml polybrene. Selection was done with 200 μg/ml G418 48 hrs after infection for 2 weeks.

The HeyA8 cells used in [Figure 3D](#fig3){ref-type="fig"} carried a lentiviral Venus-siL3 sensor vector ([@bib48]) and were infected with NucLight Red lentivirus (Essen Bioscience \#4476) with 8 μg/ml polybrene and selected with 3 μg/ml puromycin and sorted for high Venus expression 48 hr later. HeyA8 ΔshR6 clone \#2 sensor cells used in [Figure 3A--3C](#fig3){ref-type="fig"} were infected with lentiviruses generated from the Venus-CD95L sensor vector (described below) to over-express the Venus-CD95L chimeric transcript. Cells were sorted for high Venus expression 48 hr later. NB7 cells over-expressing either the Venus-CD95L sensor or the Venus-CD95 sensor (described below) used in [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"} were similarly generated.

Plasmids and constructs {#s4-3}
-----------------------

The Venus-CD95L ORF and Venus-CD95 ORF (full length) sensor vectors were created by sub-cloning the Venus-CD95L or the Venus-CD95 inserts (synthesized as a minigene by IDT with flanking XbaI RE site on the 5' end and EcoRI RE site at the 3' end in the pIDTblue vector), which are composed of the Venus ORF followed by either the CD95L ORF (accession number NM_000639.2) or the CD95 ORF (accession number BC012479.1) as an artificial 3'UTR (both lacking the A in the start codon), respectively, into the modified CD510B vector ([@bib9]) using XbaI and EcoRI. Ligation was done with T4 DNA ligase.

The pLNCX2-CD95R6MUT vector was synthesized by replacing a 403 bp fragment of the CD95 ORF insert from the pLNCX2-CD95-WT vector ([@bib26]) with a corresponding 403 bp fragment that had eight silent mutation substitutions at the shR6 site (5'-*GTGTCGCTGTAAACCAAACTT* - \> 5'-*ATGTCGCTGCAAGCCCAATTT*-3') using BstXI (NEB \#R0113) and BamHI (NEB \#R3136) restriction enzymes (mutant insert was synthesized in a pIDTblue vector with 5' end BstXI site and 3' end BamHI RE site).

Dox-inducible vectors expressing shRNAs were constructed by subcloning an annealed double-stranded DNA insert containing the sequence encoding the shRNA hairpin (sense strand: 5'-*TGGCTTTATATATCTCCCTATCAGTGATAGAGATCGNNNNNNNNNNNNNNNNNNNNNCTCGAGnnnnnnnnnnnnnnnnnnnnnTTTTTGTACCGAGCTCGGATCCACTAGTCCAGTGTGGGCATGCTGCGTTGACATTGATT*-3') into the pTIP-shR6 vector ([@bib26]). BsaBI (NEB \#R0537) and SphI-HF (NEB \#R3182) were used to digest both the pTIP-shR6 vector (to excise the shR6 insert) and the double-stranded shRNA DNA cassette insert followed by ligation with T4 DNA ligase. The template oligos were purchased from IDT. The poly-N represents the two 21 bp sequences that transcribe for the sense (*N*) and antisense (*n*) shRNA. miR-30 based shRNAs were generated by The Gene Editing and Screening Core, at Memorial Sloan Kettering, NY, by converting the 21mers expressed in the pLKO and pTIP vectors into 22mers followed by cloning into the Dox-inducible LT3REPIR vector as described ([@bib15]). A vector expressing an shRNA against Renilla luciferase was used as control ([@bib15]).

CRISPR deletions {#s4-4}
----------------

We identified two gRNAs that target upstream and downstream of the site to be deleted. These gRNAs were expected to result in the deletion of a DNA piece just large enough to remove the target site. The CRISPR gRNA scaffold gene blocks were from IDT and consisted of the DNA sequence 5'-*TGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATCCGGTACCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGNNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTCTAGACCCAGCTTTCTTGTACAAAGTTGGCATTA-3'* ([@bib42]); The poly-*NNNNNNNNNNNNNNNNNNN* represents the 19nt target sequence. The two 19nt target sequences for excision of the shL3 site (Δ41 deletion) were 5'-*CCTTGTGATCAATGAAACT*-3' (gRNA \#1) and 5'-*GTTGTTGCAAGATTGACCC*-3' (gRNA \#2). The two target sequences for the Δ227 deletion of the shR6 site were 5'-*GCACTTGGTATTCTGGGTC*-3' and 5'-*TGTTTGCTCATTTAAACAC*-3'. The two target sequences for Δ64 deletion of the siL3 site were 5'-*TAAAACCGTTTGCTGGGGC*-3' and 5'-*TATCCCCAGATCTACTGGG*-3'. Target sequences were identified using the CRISPR gRNA algorithm found at <http://crispr.mit.edu/>; only gRNAs with scores over 50 were used. These six gene blocks were sub-cloned into the pSC-B-amp/kan plasmid using the StrataClone Blunt PCR Cloning kit (Agilent Technologies \#240207).

The target sites of siL3, shL3, and shR6 were homozygously deleted from target cells by co-transfecting Cas9 plasmid with each corresponding pair of pSC-B-gRNA plasmids. Briefly, 400,000 cells were seeded per well on a 6-well plate the day prior to transfection. Each well was transfected with 940 ng of Cas9-GFP plasmid (pMJ920) ([@bib32]) and 450 ng of each pSC-B-gRNA plasmid using Lipofectamine 2000. Media was replaced next day. One to two days later, cells were sorted for the top 50% population with the highest green fluorescence. Those cells were cultured for an additional week to let them recover. The cells were then sorted by FACS (BD FACSAria SORP system) directly into 96-well plates containing a 1:1 ratio of fresh media:conditioned media for single cell cloning. Approximately two to three weeks later, single cell clones were expanded and subjected to genotyping. PCR using both a primer pair that flanked the region to be deleted and another pair containing one flanking primer and one internal primer was used to screen clones for homozygous deletion. For detection of the Δ41 deletion of the shL3 site, the flanking external primers were 5'-*TCTGGAATGGGAAGACACCT*-3' (Fr primer) and 5'- *CCTCCATCATCACCAGATCC*-3' (Rev primer), and the internal Rev primer was 5'-*ATATACAAAGTACAGCCCAGT*-3'. For detection of the Δ227 deletion of the shR6 site, the flanking external primers were 5'-*GGTGTCATGCTGTGACTGTTG*-3' (Fr primer) and 5'-*TTTAGCTTAAGTGGCCAGCAA*-3' (Rev primer), and the internal Rev primer was 5'-*AAGTTGGTTTACATCTGCAC*-3'. For detection of the Δ64 deletion of the siL3 site, the flanking external primers were 5'-*CTTGAGCAGTCAGCAACAGG*-3' (Fr primer) and 5'-*CAGAGGTTGGACAGGGAAGA*-3' (Rev primer), and the internal Rev primer was 5'-*ATATGGGTAATTGAAGGGCTG*-3'. After screening the clones, Sanger sequencing was performed to confirm that the proper deletion had occurred. Three clones were pooled for each si/shRNA target site deletion except for HeyA8 ΔshR6 for which only clone \#11 showed homozygous deletion of the shR6 site; clones \#1 and 2 were not complete shR6 deletion mutants, but frame-shift mutations did occur in each allele (as in clone \#11) making them CD95 knockout clones as depicted in [Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}.

Knockdown with pLKO lentiviruses {#s4-5}
--------------------------------

Cells were infected with the following pLKO.2 MISSION Lentiviral Transduction Particles (Sigma): pLKO.2-puro non-targeting (scramble) shRNA particles (\#SHC002V), eight non-overlapping shRNAs against human CD95L mRNA (accession number \#NM_000639), TRCN0000058998 (shL1: GCATCATCTTTGGAGAAGCAA), TRCN0000058999 (shL2: CCCATTTAACAGGCAAGTCCA), TRCN0000059000 (shL3: ACTGGGCTGTACTTTGTATAT), TRCN0000059001 (shL4: GCAGTGTTCAATCTTACCAGT), TRCN0000059002 (shL5: CTGTGTCTCCTTGTGATGTTT), TRCN0000372231 (shL6: TGAGCTCTCTCTGGTCAATTT), TRCN0000372232 (shL2': TAGCTCCTCAACTC ACCTAAT), and TRCN0000372175 (shL5': GACTAGAGGCTTGCATAATAA), and nine non-overlapping shRNAs against human CD95 mRNA (accession number NM_000043), TRCN0000218492 (shR2: CTATCATCCTCAAGGACATTA), TRCN00000 38695 (shR5: GTTGCTAGATTATCGTCCAAA), TRCN0000038696 (shR6: GTGCAGA TGTAAACCAAACTT), TRCN0000038697 (shR7: CCTGAAACAGTGGCAATAAAT), TRCN0000038698 (shR8: GCAAAGAGGAAGGATCCAGAT), TRCN0000265627 (shR27': TTTTACTGGGTACATTTTATC), TRCN0000255406 (shR6\': CCCTTGTGTTT GGAATTATAA), TRCN0000255407 (shR7': TTAAATTATAATGTTTGACTA), and TRCN0000255408 (shR8': ATATCTTTGAAAGTTTGTATT). Infection was carried out according to the manufacturer's protocol. In brief, 50,000 to 100,000 cells seeded the day before in a 6-well plate were infected with each lentivirus at an M.O.I of 3 in the presence of 8 μg/ml polybrene overnight. Media change was done the next day, followed by selection with 3 μg/ml puromycin 24 hrs later. Selection was done for at least 48 hrs until puromycin killed the non-infected control cells. For infection of NB7 cells over-expressing pLenti-CD95L cDNAs with pLKO lentiviral particles as in [Figure 1C and D](#fig1){ref-type="fig"}, cells were seeded at 5000 per well on a 24-well plate and infected with an M.O.I. of 20 to ensure complete infection. For infection of MCF-7 cells over-expressing pLNCX2-CD95 cDNAs with pLKO lentiviruses as in [Figure 1G](#fig1){ref-type="fig"}, cells were seeded at 7000 per well on a 24-well plate and infected at an M.O.I. of three. 3 μg/ml puromycin was added 48 hrs after infection. For infection of HCT116, Drosha^-/-^, and Dicer^-/-^ cells in [Figure 3E](#fig3){ref-type="fig"}, cells were seeded at 100,000 per well in a 24-well plate and infected at an M.O.I of three. 3 μg/ml puromycin was added 48 hrs after infection.

Knockdown with pTIP-shRNA viruses {#s4-6}
---------------------------------

Cells were plated at 50,000 to 100,000 cells per well in a 6-well plate. Cells were infected with lentivirus generated in 293T cells from the desired pTIP-shRNA vector in the presence of 8 μg/ml Polybrene. Media was replaced 24 hrs later. Selection was done 48 hrs after infection with 3 μg/ml puromycin. Induction of shRNA expression was achieved by adding 100 ng/ml Dox to the media. For infection with the LT3REPIR-shRNA viruses cells were plated and infected as described above for pTIP-shRNA viruses. After selection with 3 μg/ml puromycin was complete, they were plated in 96-well plates and the shRNA expression was induced by adding Dox (100 ng/ml) to the media. The cell confluency over time was measured using Incucyte.

Transfection with short oligonucleotides {#s4-7}
----------------------------------------

siRNAs were either purchased from Dharmacon ([Figures 2I](#fig2){ref-type="fig"} and [4D](#fig4){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) or synthesized by IDT ([Figure 3](#fig3){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) as sense and antisense RNA (or DNA for [Figure 3B](#fig3){ref-type="fig"}) oligos and annealed. The sense RNA oligonucleotides had 3\' two deoxy-T overhangs. The antisense RNA oligos were phosphorylated at the 5' end and had 3\' two deoxy-A overhangs. siRNAs targeting CD95L (and controls) were as follows: siRNA (Scr, sense: UGGUUUACAUGUUGUGUGA), siL1 (sense: UACCAGUGCUGAUCAUUUA), siL2 (sense: CAACGUAUCUGAGCUCUCU), siL3 (sense: GCCCUUCAAUUACCCAUAU), siL4 (sense: GGAAAGUGGCCCAUUUAAC), and siL3MUT (sense: GGACUUCAACUAGACAUCU). The siL3 DNA oligos (sense: GCCCTTCAATTACCCATAT) and Scr DNA oligos (sense: TGGTTTACATGTTGTGTGA) were used in [Figure 3B](#fig3){ref-type="fig"}. Blunt siL3 and siScr RNA oligos without the deoxynucleotide overhangs as well as siL2 and siL3 RNA oligos with Cy5-labelled 5' or 3' ends (IDT) were used in [Figure 3C](#fig3){ref-type="fig"}. DsiRNA used in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} were Dsi13.X (sense RNA oligo: CAGGACUGAG AAGAAGUAAAACCdGdT, antisense RNA oligo: ACGGUUUUACUUCUUCUCAGUCCUGUA), DsiL3 (sense RNA oligo: CAGCCCUUCAAUUACCCAUAUCCdCdC, antisense RNA oligo: GGGGAUAUGGGUAAUUGAAGGGCUGCU), Dsi-13.2 (sense RNA oligo: AUCUU ACCAGUGCUGAUCAUUUAdTdA, antisense RNA oligo: UAUAAAUGAUCAGCACUGGUAAGAUUG), Dsi-13.3 (sense RNA oligo: AAAGUAUACUUCCGGGGUCAAUCdTdT, antisense RNA oligo: AAGAUUGACCCCGGAAGUAUACUUUGG), Dsi-13.9 (sense RNA oligo: CUUCCGGGGUCAAUCUUGCAACAdAdC, antisense RNA oligo: GUUGUUGC AAGAUUGACCCCGGAAGUA), and a non-targeting DsiRNA control Dsi-NC1 (Sense:5\'-CGUUAAUCGCGUAUAAUACGCGUdAdT, antisense:5'-AUACGCGUAUUAUACGCGAUUAACGAC, IDT \#51-01-14-03). Predesigned siRNA SmartPools targeting the 11 downregulated genes were obtained from Dharmacon and used in [Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2B and C](#fig4s2){ref-type="fig"}. Each siRNA SmartPool consisted of 4 siRNAs with On-Target*plus* modification. The following SmartPools were used: L-014208--02 (NUCKS1); L-012212--00 (CAPZA1); L-018339--00 (CCT3); L-013615--00 (FSTL1); L-011548--00 (FUBP1); L-017242--00 (GNB1); L-014597--01 (NAA50); L-020893--01 (PRELID3B); L-019719--02 (SNRPE); L-003941--00 (TFRC); L-006630--00 (HIST1H1C). On-Target*plus* non-targeting control pool (D-001810--10) was used as negative control. Transfection efficiency was assessed by transfecting cells with siGLO Red (Dharmacon) followed by FACS analysis.

HeyA8 cells (and modified cells derived from parental HeyA8 cells) were seeded at 750 cells per well on a 96-well plate one day before transfection. Cells were transfected using 0.1 μl of Lipofectamine RNAiMAX reagent per well. HCT116 cells (and modified cells derived from parental HCT116 cells) were seeded at 4000 cells per well on a 96-well plate one day before transfection. 0.2 μl of Lipofectamine RNAiMAX was used for transfection. Media was changed the day after transfection.

Soluble CD95L protein rescue experiments {#s4-8}
----------------------------------------

NB7 cells were seeded at 500 cells per well in a 96-well plate. Next day, cells were infected with the scrambled pLKO lentiviruses or pLKO-shL1 lentiviruses at an M.O.I. of 20 (to achieve 100% transduction efficiency under conditions omitting the puromycin selection step) in the presence of 8 μg/ml polybrene and 100 ng/ml of S2 CD95L or LzCD95L for 16 hr. Media was replaced the next day with media containing varying concentrations of recombinant CD95L.

Real-time PCR {#s4-9}
-------------

Total RNA was extracted and purified using QIAZOL Lysis reagent (QIAGEN) and the miRNeasy kit (QIAGEN). 200 ng of total RNA was used to generate cDNA using the high-capacity cDNA reverse Transcription kit (Applied Biosystems \#4368814). cDNA was quantified using Taqman Gene expression master mix (ThermoFisher Scientific \#4369016) with specific primers from ThermoFisher Scientific for GAPDH (Hs00266705_g1), human CD95 for [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"} (Hs00163653_m1), human CD95 3'UTR in [Figure 2F](#fig2){ref-type="fig"} (custom probe, Fr primer: *GGCTAACCCCACTCTATGAATCAAT*, Rev primer: *GGCCTGCCTGTTCAGTAACT*, Probe: *CCTTTTGCTGAAATATC*), human CD95L (Hs00181226_g1 and Hs00181225_m1), the shL3 target site in CD95L in [Figure 2D](#fig2){ref-type="fig"} (custom probe, Fr primer: *GGTGGCCTTGTGATCAATGAAA*, Rev primer: *GCAAGATTGACCCCGGAAG TATA*, Probe: *CTGGGCTGTACTTTGTATATT*), and downstream of the shL3 site in [Figure 2D](#fig2){ref-type="fig"} (custom probe, Fr primer: *CCCCAGGATCTGGTGATGATG*, Rev primer: *ACTGCCCCCAGGTAGCT*, Probe: *CCCACATCTGCCCAGTAGT*).

To perform arrayed real-time PCR ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), total RNA was extracted and used to make cDNA as described for standard real-time PCR. For Taqman Low Density Array (TLDA) profiling, custom-designed 384-well TLDA cards (Applied Biosystems \#43422489) were used and processed according to the manufacturer's instructions. Briefly, 50 µl cDNA from each sample (200 ng total input RNA) was combined with 50 µl TaqMan Universal PCR Master Mix (Applied Biosystems) and hence a total volume of 100 µl of each sample was loaded into each of the 8 sample loading ports on the TLDA cards that were preloaded with assays from Thermofisher Scientific for human GAPDH control (Hs99999905_m1) and for detection of ATP13A3 (Hs00225950_m1), CAPZA1 (Hs00855355_g1), CCT3 (Hs00195623_m1), FSTL1 (Hs00907496_m1), FUPB1 (Hs00900762_m1), GNB1 (Hs00929799_m1), HISTH1C (Hs00271185_s1), NAA50 (Hs00363889_m1), NUCKS1 (Hs01068059_g1), PRELID3B (Hs00429845_m1), SNRPE (Hs01635040_s1), and TFRC (Hs00951083_m1) after the cards reached room temperature. The PCR reactions were performed using Quantstudio 7 (ThermoFisher Scientific). Since each of the port loads each sample in duplicates on the TLDA card and because two biological replicates of each sample were loaded onto two separate ports, quadruplicate Ct values were obtained for each sample. Statistical analysis was performed using Student's t test. Cells were plated at 600,000 per 15 mm dish (Greiner CELLSTAR, cat\#P7237, Sigma) after one day of puromycin selection. Total RNA was harvested at 50 hrs after plating for RNAseq analysis.

Western blot analysis {#s4-10}
---------------------

Protein extracts were collected by lysing cells with RIPA lysis buffer (1% SDS, 1% Triton X-100, 1% deoxycholic acid). Protein concentration was quantified using the DC Protein Assay kit (Bio-Rad, Hercules, CA). 30 μg of protein were resolved on 8--12% SDS-PAGE gels and transferred to nitrocellulose membranes (Protran, Whatman) overnight at 25 mA. Membranes were incubated with blocking buffer (5% non-fat milk in 0.1% TBS/Tween-20) for 1 hr at room temperature. Membranes were then incubated with the primary antibody diluted in blocking buffer over night at 4°C. Membranes were washed 3 times with 0.1% TBS/Tween-20. Secondary antibodies were diluted in blocking buffer and applied to membranes for 1 hr at room temperature. After 3 more additional washes, detection was performed using the ECL reagent (Amersham Pharmacia Biotech) and visualized with the chemiluminescence imager G:BOX Chemi XT4 (Synoptics).

CD95 surface staining {#s4-11}
---------------------

Cell pellets of about 10^6^ cells were resuspended in about 100 μl of PBS on ice. After resuspension, 4 μl of either anti-CD95 primary antibody (BD \#556640) conjugated with fluorescein isothiocyanate (FitC), or the matching Isotype control (BD \#551954), Mouse IgG1 κ conjugated with FitC, were added. Cells were incubated on ice at 4°C, in the dark, for 25 min, washed twice with PBS, and percent green cells were determined by flow cytometry (Becton, Dickinson).

Cell death quantification (DNA fragmentation) {#s4-12}
---------------------------------------------

A cell pellet (500,000 cells) was resuspended in 0.1% sodium citrate, pH 7.4, 0.05% Triton X-100, and 50 μg/ml propidium iodide. After resuspension, cells were incubated 2 to 4 hrs in the dark at 4°C. The percent of subG1 nuclei (fragmented DNA) was determined by flow cytometry.

Cell growth and fluorescence over time {#s4-13}
--------------------------------------

After treatment/infection, cells were seeded at 500 to 4000 per well in a 96-well plate at least in triplicate. Images were captured at indicated time points using the IncuCyte ZOOM live cell imaging system (Essen BioScience) with a 10x objective lens. Percent confluence, red object count, and the green object integrated intensity were calculated using the IncuCyte ZOOM software (version 2015A).

RNA-Seq analysis {#s4-14}
----------------

The following describes the culture conditions used to produce samples for RNA-Seq in [Figure 4](#fig4){ref-type="fig"}. HeyA8 ΔshR6 clone \#11 cells were infected with pLKO-shScr or pLKO-shR6. A pool of three 293T ΔshL3 clones was infected with either pTIP-shScr or pTIP-shL3. After selection with puromycin for 2 days, the pTIP-infected 293T cells were plated with Dox in duplicate at 500,000 cells per T175 flask. The pLKO-infected HeyA8 cells were plated at 500,000 cells per flask. Total RNA was harvested 50 hrs and 100 hrs after plating. In addition, 293T cells were infected with either pLKO-shScr or pLKO-shL1 and RNA was isolated (100 hrs after plating) as described above for the infection with shR6. Finally, HeyA8 cells were transfected with RNAiMAX in 6-wells with siScr (NT2) or siL3 oligonucleotides (Dharmacon) at 25 nM. The transfection mix was removed after 9 hrs and RNA harvested 48 hrs after transfection.

Total RNA was isolated using the miRNeasy Mini Kit (Qiagen, Cat.No. 74004) following the manufacturer's instructions. An on-column digestion step using the RNAse-free DNAse Set (Qiagen, Cat.No.: 79254) was included for all RNA-Seq samples.

RNA libraries were generated and sequenced (Genomics Core facility at the University of Chicago). The quality and quantity of the RNA samples were checked using an Agilent bio-analyzer. Paired end RNA-SEQ libraries were generated using Illumina TruSEQ TotalRNA kits using the Illumina provided protocol (including a RiboZero rRNA removal step). Small RNA-SEQ libraries were generated using Illumina small RNA SEQ kits using the Illumina provided protocol. Two types of small RNA-SEQ sub-libraries were generated: one containing library fragments 140--150 bp in size and one containing library fragments 150--200 bp in size (both including the sequencing adaptor of about 130 bp). All three types of libraries (one RNA-SEQ and two small RNA-SEQ) were sequenced on an Illumina HiSEQ4000 using Illumina provided reagents and protocols. Adaptor sequences were removed from sequenced reads using TrimGalore (<https://www.bioinformatics.babraham.ac.uk/projects/trim_galore>), and the trimmed reads were mapped to the hg38 assembly of the human genome with Tophat and bowtie2. Raw read counts were then assigned to genes using HTSeq. Differential gene expression was analyzed with the R Bioconductor DESeq2 package ([@bib40]) using shrinkage estimation for dispersions and fold changes to improve stability and interpretability of estimates. P values and adjusted P values were calculated using the DESeq2 package.

To identify differentially abundant RNAs in cells expressing either shL3 or shR6, using a method unbiased by genome annotation, we also analyzed the raw 100 bp reads for differential abundance. First, the second end in each paired end read was reverse complemented, so that both reads were on the same strand. Reads were then sorted and counted using the core UNIX utilities sort and uniq. Reads with fewer than 128 counts across all 16 samples were discarded. A table with all of the remaining reads was then compiled, summing counts from each sequence file corresponding to the same sample. This table contained a little over 100,000 reads. The R package edgeR (<http://bioinformatics.oxfordjournals.org/content/26/1/139>) was used to identify differentially abundant reads, and then these reads were mapped to the human genome using blat (<http://genome.cshlp.org/content/12/4/656.abstract>) to determine chromosomal location whenever possible. Homer (<http://homer.salk.edu/homer/>) was used to annotate chromosomal locations with overlapping genomic elements (such as genes). Raw read counts in each sequence file were normalized by the total number of unique reads in the file.

To identify the most significant changes in expression of RNAs both methods of RNAs-Seq analyses (alignment and read based) were used to reach high stringency. All samples were prepared in duplicate and for each RNA the average of the two duplicates was used for further analysis. In the alignment-based analysis, only RNAs that had a base mean of \>2000 reads and were significantly deregulated between the groups (adjusted p-value\<0.05) were considered for further analysis. RNAs were scored as deregulated when they were more than 1.5 fold changed in the shL3 expressing cells at both time points and in the shR6 expressing cells at either time points (each compared to shScr expressing cells) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). This was done because we found that the pLKO-driven expression of shR6 was a lot lower than the pTIP-driven expression of shL3 (see the quantification of the two shRNAs in [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). This likely was a result of the reduced cellular responses in the shR6 expressing cells. In the read-based analysis, reads were only considered if they had both normalized read numbers of \>10 across the samples in each treatment, as well as less than two fold variation between duplicates and \>1.5 fold change between treatment groups at both time points and both cell lines ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). After filtering, reads were mapped to the genome and associated with genes based on chromosomal localization. Finally, all RNAs were counted that showed deregulation in the same direction with both methods. This resulted in the identification of 11 RNAs that were down and 1 that was upregulated in cells exposed to the shRNAs shL3 and shR6. To determine the number of seed matches in the 3\'UTR of downregulated genes, the 3\'UTRs of the 11 mRNAs were extracted from the Homo sapiens gene (GRCh38.p7) dataset of the Ensembl 86 database using the Ensembl Biomart data mining tool. For each gene, only the longest deposited 3\'UTR was considered. Seed matches were counted in all 3\'UTRs using in-house Perl scripts.

GSEA used in [Figure 4D](#fig4){ref-type="fig"} was performed using the GSEA v2.2.4 software from the Broad Institute (<http://software.broadinstitute.org/gsea>); 1000 permutations were used. The Sabatini gene lists ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) were set as custom gene sets to determine enrichment of survival genes versus the nonsurvival control genes in downregulated genes from the RNA seq data; Adjusted p-values below 0.05 were considered significantly enriched. The GO enrichment analysis shown in [Figure 4F](#fig4){ref-type="fig"} was performed using all genes that after alignment and normalization were found to be at least 1.5 fold downregulated with an adjusted p values of \< 0.05, using the software available on [www.Metascape.org](http://www.Metascape.org) and default running parameters.

Conversion of shL3 and shR6 to siRNAs {#s4-15}
-------------------------------------

From the RNA-Seq analysis with HeyA8 ΔshR6 infected with pLKO-shR6 and 293T ΔshL3 clones infected pTIP-shL3, we analyzed the mature double-stranded RNAs derived from pLKO-shR6 and pTIP-shL3 and found that the most abundant RNA forms were both shifted by one nucleotide. Based on these most abundant species observed after cellular processing, we converted shL3 and shR6 sequences to siRNAs. The genomic target sequence in shL3 (21nt) is 5'-ACUGGGCUGUACUUUGUAUAU-3'. For the shL3 =\> siL3 sense strand, one G was added before the A on the 5' end while the last U on the 3' end was deleted, and second and third to the last ribonucleotides on the 3' end (UA) were replaced with deoxyribonucleotides for stabilization. For shL3 =\> siL3 antisense strand, the last three nucleotides on the 5' end (AUA) were deleted and one U and two dTs (UdTdT) were added after the last U on the 3'end. The shL3 =\> siL3 sense strand is 5'- GACUGGGCUGUACUUUGUAdTdA-3' and antisense strand is 5'-/5Phos/UACAAAGUACAGCCCAGUUdTdT-3'. The shR6 =\> siRNA was designed in a similar fashion except that two Gs instead of one G were added to the 5' end of the sense strand while UUdTdT instead of UdTdT was added to the 3' end of the antisense strand. The genomic target sequence in shR6 (21nt) is 5'-GUGCAGAUGUAAACCAAACUU-3'. The shR6 =\> siR6 sense strand is 5'-GGGUGCAGAUGUAAACCAAAdCdT-3' and antisense strand is 5'-/5Phos/UUUGGUUUACAUCUGCACUUdTdT-3'. Both shL3 =\> siL3 and ShR6 =\> siR6 siRNA duplexes were purchased from Dharmacon.

Construction of pTIP-shRNA libraries {#s4-16}
------------------------------------

The pTIP-shRNA libraries were constructed by subcloning libraries of 143nt PCR inserts of the form 5'-*XXXXXXXXXXXXXXXXXXXXXXXXXXATAGAGATCGNNNNNNNNN NNNNNNNNNNNNCTCGAGNNNNNNNNNNNNNNNNNNNNNTTTTTGTACCGAGCTCGGATCCACTAGTCCAGTGTGGGCATGCTGCGTTGACATTGATT*-3' into the pTIP-shR6 vector after excising the shR6 insert. The poly-N region represents the 21-mer sense and antisense shRNA hairpin. The intervening CTCGAG is the loop region of the shRNA. The 5 libraries targeting Venus, CD95L ORF, CD95L 3'UTR, CD95 ORF, or CD95 3'UTR were composed of every possible 21-mer shRNA (i.e. each nearest neighbor shRNA was shifted by 1 nucleotide). These libraries were synthesized together on a chip as 143 bp single-stranded DNA oligos (CustomArray Inc, Custom 12K oligo pool). Each shRNA pool had its own unique 5' end represented by the poly-*X* region. This allowed selective amplification of a particular pool using 1 of 5 unique Fr primers (CD95L ORF: 5'-*TGGCTTTATATATCTCCCTATCAGTG*-3', CD95L 3' UTR: 5'-*GGTCGTCCTATCTATTATTATTCACG*-3', CD95 ORF: 5'-*TCTTGTGTCCAGACCAATTTATTTCG*-3', CD95 3'UTR: 5'-*CTCATTGACTATCGTTTTAGCTACTG*-3', Venus: 5'-*TATCATCTTTCATGATGACTTTCCGG*-3') and the common reverse primer 5'-*AATCAATGTCAACGCAGCAT*-3'. Phusion High Fidelity Polymerase (NEB \#M0530) was used to amplify each library pool; standard PCR conditions were used with an annealing temperature of 61°C and 15 cycles. PCR reactions were purified using PCR Cleanup kit (QIAGEN). The pTIP-shR6 vector and each of the amplified libraries were digested with SphI-HF and BsaBI. Digested PCR products were run on either a 2% Agarose gel or a 20% polyacrylamide (29:1) gel made with 0.5 x TBE buffer. PCR products were extracted using either Gel Extraction kit (QIAGEN) for extraction from Agarose gels or via electro-elution using D-Tube Dialyzer Mini columns (Novagen \#71504). Purified PCR inserts were then ligated to the linearized pTIP vector with T4 DNA ligase for 24 hr at 16°C. The ligation mixtures were transformed via electroporation in MegaX DH10B T1 cells (Invitrogen \#C6400) and plated on 24 cm ampicillin dishes. At least 10 colonies per pool were picked and sequenced to verify successful library construction. After verification, all colonies per library were pooled together and plasmid DNA extracted using the MaxiPrep kit (QIAGEN). The 5 pTIP-shRNA library DNA preps were used to produce virus in 293T cells.

Lethality screen with pTIP-shRNA libraries {#s4-17}
------------------------------------------

NB7 cells were seeded at 1.5 × 10^6^ per 145 cm^2^ dish. Two dishes were infected with each of the 5 libraries with a transduction efficiency of about 10% to 20%. Media was replaced next day. Infected cells were selected with 1.5 μg/ml puromycin. Cells infected with the Venus, CD95L ORF, and CD95L 3'UTR-targeting libraries were pooled in a 1:1:1 ratio to make the CD95L cell pool. Likewise, cells infected with the Venus, CD95 ORF, and CD95 3'UTR-targeting libraries were pooled to make the CD95 receptor cell pool. The CD95 and the CD95L cell pools were plated separately each in 2 sets of duplicates seeded at 600,000 cells per 145 cm^2^ dish. One set received 100 ng/ml Dox, and the other one was left untreated (total of 4 dishes per combined pool; 2 received no treatment and 2 received Dox). Cells infected with the different libraries were also plated individually in triplicate with or without Dox on a 96-well plate to assess the overall toxicity of each pool. DNA was collected from each 145 cm^2^ dish 9 days after Dox addition.

The shRNA barcodes were amplified from the harvested DNA template using NEB Phusion Polymerase with 4 different pairs of primers (referred to as N, N + 1, N + 2, and N + 3) in separate reactions per DNA sample. The N pair consisted of the primers originally used to amplify the CD95L ORF library (Fr: 5'-*TGGCTTTATATATCTCCCTATCAGTG*-3' and Rev: 5'-*AATCAATGTCAACGCAGCAT*-3'). The N + 1 primers had a single nucleotide extension at each 5' end of the N primers corresponding to the pTIP vector sequence (Fr: 5'-*TTGGCTTTATATATCTCCCTATCAGTG*-3' and Rev: 5'-*TAATCAATGTCAACGCAGCAT*-3'). The N + 2 primers had 2 nucleotide extensions (Fr: 5'-*CTTGGCTTTATATATCTCCCTATCAGTG*-3' and Rev: 5'-*ATAATCAATGTCAACGCAGCAT*-3'), and the N + 3 primers had 3 nucleotide extensions (Fr: 5'-*TCTTGGCTTTATATATCTCCCTATCAGTG*-3' and Rev: 5'-*AATAATCAATGTCAACGCAGCAT*-3'). The barcodes from the pTIP-shRNA library plasmid preparations were also amplified using Phusion Polymerase with the N, N + 1, N + 2, and N + 3 primer pairs. The shRNA barcode PCR products were purified from a 2% Agarose gel and submitted for 100 bp paired-end deep sequencing (Genomics Core facility at the University of Chicago). DNA was quantitated using the Qubit. The 4 separate PCR products amplified using N, N + 1, N + 2, and N + 3 were combined in equimolar amounts for each sample. Libraries were generated using the Illumina TruSeq PCR-free kit using the Illumina provided protocol. The libraries were sequenced using the HiSEQ4000 with Illumina provided reagents and protocols. Raw sequence counts for DNAs were calculated by HTSeq. shRNA sequences in the PCR pieces of genomic DNA were identified by searching all reads for the sense sequence of the mature shRNA plus the loop sequence CTCGAG. To avoid a division by zero problem during the subsequent analyses all counts of zero in the raw data were replaced with 1. A few sequences with a total read number \<10 across all plasmids reads were not further considered. In the CD95L pool this was only one shRNA (out of 2362 shRNAs) (L792\') and in the CD95 20 shRNAs (out of 3004 shRNAs) were not represented (R88, R295, R493, R494, R496, R497, R498, R499, R213\', R215\', R216\', R217\', R220\', R221\', R222\', R223\', R225\', R226\', R258\', R946\', R1197\', R423\'). While most shRNAs in both pools had a unique sequence two sequences occurred 6 times (L605\', L607\', L609\', L611\', L613\', L615\', and L604\', L606\', L608\', L610\', L612\', L614\'). In these cases, read counts were divided by 6. Two shRNAs could not be evaluated: 1) shR6 in the CD95 pool. It had a significant background due to the fact that pTIP-shR6 was used as a starting point to clone all other shRNAs. 2) shL3 was found to be a minor but significant contaminant during the infection of some of the samples. For each condition, two technical duplicates and two biological duplicates were available. To normalize reads to determine the change in relative representation of shRNAs between conditions, the counts of each shRNA in a subpool (all replicates and all conditions) was divided by the total number of shRNAs in each subpool (%). First, the mean of the technical replicates (R1 and R2) was taken. To analyze the biological replicates and to determine the changes between conditions, two analyses were performed: 1) The change in shRNA representation between the cloned plasmid library and cells infected with the library and then cultured for 9 days without Dox (infection -Dox). Fold downregulation was calculated for each subpool as \[(plasmid %/-Dox1 %+plasmid %/-Dox2 %)/2\]. 2) The difference in shRNA composition between the infected cells cultured with (infection +Dox) and without Dox. Fold downregulation was calculated for each subpool as \[(-Dox1 %/+Dox1%)+(-Dox1 %/+Dox2%)+(-Dox2 %/+Dox1%)+(-Dox2 %/+Dox2%)/4\]. Only shRNAs were considered that were at least 5-fold underrepresented in either of the two analyses (data in [Supplementary file 3](#supp3){ref-type="supplementary-material"}).

The toxicity index (TI) and GC content analysis {#s4-18}
-----------------------------------------------

The TI in [Figure 7A](#fig7){ref-type="fig"} is defined by the sum of the counts of a 6mer or 8mer seed match in the 3\'UTRs of critical survival genes divided by the seed match counts in the 3\'UTRs of nonsurvival genes. We used the 1882 survival genes recently described in a CRISPR/Cas9 lethality screen by Wang et al. ([@bib70]). The survival genes were defined by having a CRISPR score of \<−0.1 and an adjusted p-value of \<0.05. We chose as a control group to these top essential genes the bottom essential genes using inverse criteria (CRISPR score of \>0.1 and adjusted p-value of \<0.05) and are referring to them as the 'nonsurvival genes'. Both counts were normalized for the numbers of genes in each gene set. 3\'UTRs were retrieved as described above. For the survival genes 1846 and for the nonsurvival genes 416 3\'UTRs were found. For each gene, only seed matches in the longest 3\'UTR were counted. The TI was calculated for each of the 4096 possible 6mer combinations and each of the 65536 possible 8mer combinations ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). These numbers were then assigned to the results of the shRNA screen ([Supplementary file 5](#supp5){ref-type="supplementary-material"}). An alternative TI was calculated in [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"} and is based on the top 850 most highly expressed survival genes (all expressed \>1000 average reads) and 850 expression matched genes not described to be critical for cancer cell survival were selected as controls.

For the analyses in [Figure 7C and D](#fig7){ref-type="fig"}, the GC content % was calculated for every 6mer in the CD95L ORF shRNA pool. The GC content % was then plotted against the log(Fold down) for each shRNA in the CD95L ORF shRNA after infection (compared to the plasmid composition) in [Figure 7C](#fig7){ref-type="fig"} and after addition of Dox (compared to cells infected but not treated with Dox) in [Figure 7D](#fig7){ref-type="fig"}. In [Figure 7E](#fig7){ref-type="fig"}, the log(TI) and GC content % was extracted for every possible 6mer and plotted. Pearson correlation coefficient and associated p-value were calculated in R3.3.1.

Sylamer analysis {#s4-19}
----------------

Sylamer is a tool to test for the presence of RNAi-type regulation effects from a list of differentially expressed genes, independently from small RNA measurements ([@bib69]) (<http://www.ebi.ac.uk/research/enright/software/sylamer>). For short stretches of RNA (in this case length 6, 7, and 8 in length corresponding to the lengths of the determinants of seed region binding in RNAi-type binding events), Sylamer tests for all possible motifs of this length whether the motif occurrences are shifted in sequences associated with the list under consideration, typically 3\'UTRs when analyzing RNAi-type binding events. A shift or enrichment of such a motif towards the down-regulated end of the gene list is consistent with upregulation of a small RNA that has the motif as the seed region. Sylamer tests in small increments along the list of genes, using a hypergeometric test on the counts of a given word, comparing the leading part of the gene list to the universe of all genes in the list. For full details, refer to ([@bib69]). Enriched motifs stand out from the back-ground of all motifs tested, as visible in the Sylamer plot. The plot consist of many different lines, each line representing the outcomes of a series of tests for a single word, performed along regularly spaced intervals (increments of 200 genes) of the gene list. Each test yields the log-transformed P-value arising from a hypergeometric test as indicated above. If the word is enriched in the leading interval, the log-transformed value has its value plotted on the positive y-axis (sign changed), if the word is depleted the log-transformed value is plotted on the negative y-axis. 3\'UTRs were used from Ensembl, version 76. As required by Sylamer, they were cleaned of low-complexity sequences and repetitive fragments using respectively Dust ([@bib47]) with default parameters and the RSAT interface ([@bib44]) to the Vmatch program, also run with default parameters. Sylamer (version 12--342) was run with the Markov correction parameter set to 4.

Statistical analyses {#s4-20}
--------------------

Continuous data were summarized as means and standard deviations (except for all IncuCyte experiments where standard errors are shown) and dichotomous data as proportions. Continuous data were compared using t-tests for two independent groups and one-way ANOVA for 3 or more groups. For evaluation of continuous outcomes over time, two-way ANOVA was used with one factor for the treatment conditions of primary interest and a second factor for time treated as a categorical variable to allow for non-linearity. Comparisons of single proportions to hypothesized null values were evaluated using binomial tests. Statistical tests of two independent proportions were used to compare dichotomous observations across groups.

The effects of treatment on wild-type versus either Dicer^-/-^ or Drosha^-/-^ cells were statistically assessed by fitting regression models that included linear and quadratic terms for value over time, main effects for treatment and cell type, and two- and three-way interactions for treatment, cell-type and time. The three-way interaction on the polynomial terms with treatment and cell type was evaluated for statistical significance since this represents the difference in treatment effects over the course of the experiment for the varying cell types.

To test if higher TI is enriched in shRNAs that were highly downregulated, p-values were calculated based on permutated datasets using Mann-Whitney U tests. The ranking of TI was randomly shuffled 10,000 times and the W statistic from our dataset was compared to the distribution of the W statistic of the permuted datasets. Test of enrichment was based on the filtered data of at least 5-fold difference, which we define as a biologically meaningful. Fisher Exact Tests were performed to assess enrichment of downregulated genes (i.e. \>1.5 downregulated with adjusted p-value\<0.05) amongst genes with at least one si/shRNA seed match. All statistical analyses were conducted in Stata 14 (RRID:[SCR_012763](https://scicrunch.org/resolver/SCR_012763)) or R 3.3.1 in Rstudio (RRID:[SCR_000432](https://scicrunch.org/resolver/SCR_000432)).
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The following dataset was generated:

Peter M2017Cell Death-Inducing Sequences with RNAi Activity Embedded in the Genes of CD95 and CD95L<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87817>Publicly available at NCBI Gene Expression Omnibus (accession no: GSE87817)

The following previously published datasets were used:
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Decision letter

Settleman

Jeffrey

Reviewing Editor

Calico Life Sciences

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"CD95L derived si- and shRNAs and the CD95L mRNA kill cancer cells through an RNAi mechanism by targeting survival genes\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Charles Sawyers as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: John G Doench (Reviewer \#1); Gregory J Hannon (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Previously, the authors conducted a study that described DICE (\"Death induced by CD95R/L elimination\"), in which they show that depletion of these genes by RNAi results in cell death across a dozen cancer cell lines (Hadji et al., 2014). Here, they follow-up on this observation by fine-mapping the cause of DICE and show that the viability effect triggered by these RNAi reagents is actually not dependent on the target genes, but rather on a seed-based (i.e. microRNA-like) off-target effect of the RNAi reagents, leading to a new acronym, DISE (death induced by survival gene elimination).

Essential revisions:

1\) The consensus view among reviewers is that the emphasis in the manuscript is misplaced. It is largely about off-target effects of RNAi reagents, and has little to do with CD95 or CD95L. If the conclusion of this manuscript is that some seeds are more likely to have viability effects than others, then the focus should be on that conclusion. As written, the manuscript is very CD95-centric, which implies that there is something special about this gene.

2\) Since this manuscript is really about generic off-target effects, then there are additional resources that could be used to better analyze this phenomenon. For example, the TRC library has been screened against hundreds of cell lines and those data are available (Cowley et al., Sci. Data, 2014), and it would be important to thoroughly analyze those data to see if these observations here generalize well.

3\) Additionally, as mentioned in the last paragraph of the subsection "DISE is caused by loading of the guide strand of toxic si/shRNAs into the RISC", the inactivity of miR-30 backbone shRNAs to produce this response deserves much more treatment than a \"data not shown.\" If the off-target effects arise because of something specific to the TRC shRNAs used, that mechanism needs to be characterized. If it is purely an expression-level difference, that needs to be documented. One potential experimental approach could use transient transfection of siRNAs -- which can be used at different doses, or with pools of siRNAs to represent the different Dicer products of TRC shRNAs.

4\) The authors produced 3 different target deletions (ΔsiL3, ΔshL3 and ΔshR6) in 293T or HeyA8 cells to show that expression of the si or shRNAs, even in the absence of the target, is still lethal. The deletions seem to produce frame-shift mutations in the coding sequence (as the nt deleted are not a multiple of 3). The authors indeed show that ΔshR6 produces a protein knockout, which they use for a different experiment (Figure 1---figure supplement 3). This provokes the question of whether this is also the case for ΔsiL3 and ΔshL3 and whether it is appropriate to call them \"target site\" mutants if they are indeed functional knockouts. The authors state in their Introduction \"after deleting the CD95 gene tumors barely grew in vivo (Chen et al., 2010; Hadji et al., 2014)\" so maybe they could comment on the fact that HeyA8 ΔshR6, being a functional knockout and not exclusively a target site mutant grows similar to the parental cell line ([Figure 1H](#fig1){ref-type="fig"}).

5\) In [Figure 6](#fig6){ref-type="fig"} enforced expression of the CD95L mRNA is toxic in HeyA8 cells. However, in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, the CD95L-WT ORF is expressed (together with a scramble shRNA) and there is no observable increase in% subG1 compared to expression of vector only (together with a scramble shRNA) in either NB7 cells (panel D) or MCF-7 (panel G). Could the authors please comment on whether there are any other variables we should take into account or whether this is a cell type-specific phenotype. It is difficult to understand that NB7 lack caspase-8 but if they show the toxicity phenotype upon expression of the si/shRNAs and if over-expression of the CD95L is mediating the same phenotype, the model would predict CD95L would still cause lethality of this cell line.

6\) The authors perform a pooled screen to identify the most toxic sequences in the CD95 and CD95L genes ([Figure 5](#fig5){ref-type="fig"}). The pool screen analysis is performed comparing the final time points to the plasmid pool. This is concerning as virus production and infection could also lead to biases in the shRNA representation. As it stands, it could very well be that many of the \"depleted\" shRNAs were never present in the cells to begin with. This leads to particular concern about the results in the absence of doxycycline. The authors state that the depletion observed without adding dox is most likely due to leakiness in the Tet-on system (subsection "Identification of toxic shRNAs in the CD95L and CD95 mRNAs", second paragraph). However, in their initial experiments ([Figure 1G](#fig1){ref-type="fig"}) they expressed the highly toxic shRNA shL3 in 293T without any evidence of toxicity for at least 4 days. Thus, it would be very important to show the depletions observed in this pooled screen are indeed biological. Since the authors do not seem to have an initial post-infection time point to compare to, they could produce virus following the same set up and show that plasmid representation roughly corresponds to the shRNAs cloned from cells right after infection.

7\) Regarding the analysis of AGO-bound small RNAs that align to the CD95L, does the analysis take into account the possibility of PCR duplicates? Also, strand information is essential if the model is that this CD95L derived small RNAs are mediating knockdown of survival genes. The analysis text does not specify whether BLAST was run with any strand specificity so it would be essential for the authors to clarify.

10.7554/eLife.29702.033

Author response

> Essential revisions:
>
> 1\) The consensus view among reviewers is that the emphasis in the manuscript is misplaced. It is largely about off-target effects of RNAi reagents, and has little to do with CD95 or CD95L. If the conclusion of this manuscript is that some seeds are more likely to have viability effects than others, then the focus should be on that conclusion. As written, the manuscript is very CD95-centric, which implies that there is something special about this gene.

We agree with the reviewers that what started out as a CD95 project has turned into an RNAi toxicity project. However, the starting point was indeed CD95 centric, as it developed from the observation that \>80% of all tested si/shRNAs designed to target either CD95 or CD95L were toxic to all cancer cell lines, even in the absence of the targets. Based on these data we were faced with the question: in general are 80% of all commercially designed si/shRNAs toxic to cells via an off-target effect or is there something special about CD95 and CD95L? It was unlikely that the majority of all si/shRNAs targeting a gene would be toxic. If that were the case, RNAi would not have become such a widely-used tool. As this manuscript contains mostly data on si/shRNAs derived from CD95 or CD95L, we must discuss aspects of this work in the context of CD95/CD95L. However, we have now modified the manuscript to make clear that CD95 and CD95L serve as a model to study the toxic effects of si/shRNAs containing certain seed sequences. We have restructured the Introduction and whenever possible, in the context of a section, we are now referring to toxic seed containing si/shRNAs rather than to CD95/CD95L derived si/shRNAs. In fact, in a review that will be published shortly (title: \"DISE -- An RNAi Off-Target Effect that Kills Cancer Cells\") that was made available to the reviewers, we do discuss the DISE effect in more general terms not directly related to CD95. Most importantly, following the consensus advice of the reviewers, we have changed the title of the manuscript to reflect the scope of our work that goes beyond CD95 and CD95L. Finally, we have moved data on the toxic activity of the CD95L ORF into a future manuscript to maintain the focus on toxic si/shRNAs in this one.

We agree with the reviewers in that CD95 or CD95L are not unique. We assume there must be many other coding and also noncoding genes that can contain sequences that when expressed as si/shRNAs will be toxic.

In another recent manuscript, we explored the question of whether other genes contain such toxic sequences (Patel and Peter, 2017, Cell Cycle, in press). We focused on a set of tumor suppressors (since they were least likely to be cancer survival genes) among a list of 651 survival genes that came out of our genome-wide shRNA survival screen (Hadji et al., 2014, Cell Rep. 10:208). By focusing strictly on morphological and biochemical changes typical for cells undergoing DISE as described by us before (Hadji et al., 2014, Cell Rep. 10:208), we identified five other genes (all putative tumor suppressors) for which at least two of the commercially available shRNAs killed multiple cancer cells in a way consistent with DISE. We also demonstrate in Patel and Peter that this is not a general phenomenon associated with use of TRC library shRNAs. None of the 9 available shRNAs targeting the tumor suppressors p53 or PTEN were toxic (Patel and Peter, 2017, Cell Cycle, in press). In summary, we have clarified in the revised manuscript that what we report for CD95/CD95L is likely not unique to these two genes, and that it is more likely that multiple genes in the genome contain sequences that can give rise to toxic seeds. As a result, we have refocused the manuscript away from CD95/CD95L as much as possible and now place more focus on the activities of toxic seeds.

> 2\) Since this manuscript is really about generic off-target effects, then there are additional resources that could be used to better analyze this phenomenon. For example, the TRC library has been screened against hundreds of cell lines and those data are available (Cowley et al., Sci. Data, 2014), and it would be important to thoroughly analyze those data to see if these observations here generalize well.

We would like to thank the reviewers for directing us to this published work. We have carefully examined the cited analysis and identified the data associated with shRNAs from their screen that we also tested. We have added the result of this analysis as new [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}. The shRNAs we have tested here were found in this study to kill the following percentage of the 216 tested cells in their screen: shL4 (99.5%), shL1 (96.8%), shR6 (88.9%), shR7 (75%), shL2 (67.1%), shR5 (38.4%, shL5 (26.4%), and shR8 (21.3%). In addition to the shRNAs tested by us, these authors also tested an additional CD95 targeting sequence (we now call shR3). It was found to be toxic to 71.8% of the 216 cell lines. Their screen did not include shL3 but consistent with our data, shL1 and shR6 were found to be two of the most toxic shRNAs. Interestingly, the authors did not consider the data on any of the CD95L targeting shRNAs and half of the ones targeting CD95 to be significant as they received a low consistency score. A high consistency score predicts that the observed phenotype (cell death or growth reduction in this case) is caused by knocking down the targeted gene (on-target activity) (Shao et al., 2013, Genome Res, 23:665). Assuming each shRNA only targets one gene, that approach made sense. However, in our case, we know it is only the seed region and the targeted transcriptome that determines toxicity, resulting in an off-target effect. Thus, their exclusion of CD95L shRNAs only supports our conclusions.

Ours and their analysis agree that the majority of tested shRNAs targeting either CD95 or CD95L (67%) were toxic to the majority of all tested solid and hematopoietic cancer cell lines most likely through the offtarget effect we describe. The reason we identified a somewhat higher percentage of toxic shRNAs targeting CD95 and CD95L might be due to the fact that the shRNAs in our screen and in our experiments were tested individually, whereas the Cowley study used pooled libraries.

Also in agreement with our data, overall, CD95L-derived shRNAs are more toxic than CD95-derived shRNAs. Clearly the CD95L targeting shRNAs depleted in the largest percentage of the cell lines in their screen among the 9 we also tested are shL1 and shL4 (see new [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Consistent with this higher underrepresentation of CD95L-derived shRNAs, our data on the shRNA screen which identified the highest number of underrepresented and toxic shRNAs in the ORF of CD95L. We have added this result and discussion to the revised manuscript.

Finally, we would like to reiterate that the toxicity we describe is not limited to shRNAs of the TRC library. We observed similar toxicities using independent sets of siRNAs, Dsi-RNAs and also by inducible expression of shRNAs (see [Figure 1---figure supplement 1A and B](#fig1s1){ref-type="fig"}, (Hadji et al., 2014, Cell Rep. 10:208)). We even successfully generated toxic siRNAs based on the processing (determined by RNA-Seq) of two of our most toxic shRNAs (shL3 and shR6) (see [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). These data support the conclusion that it is not the platform or the delivery that determines toxicity but, as recognized by the reviewers, the seed sequence.

> 3\) Additionally, as mentioned in the last paragraph of the subsection "DISE is caused by loading of the guide strand of toxic si/shRNAs into the RISC", the inactivity of miR-30 backbone shRNAs to produce this response deserves much more treatment than a \"data not shown.\" If the off-target effects arise because of something specific to the TRC shRNAs used, that mechanism needs to be characterized. If it is purely an expression-level difference, that needs to be documented. One potential experimental approach could use transient transfection of siRNAs -- which can be used at different doses, or with pools of siRNAs to represent the different Dicer products of TRC shRNAs.

To support our statement on the activity of miR-30 based shRNAs, we have added the results of the miR-30 based shRNAs to the revised manuscript as new [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}. Our most toxic TRC based shRNA sequences (shL1, shL3, shL4, shR5, shR6, and shR7) were converted into miR-30 based hairpins and cloned into the Tet-inducible LT3REPIR vector by the Memorial Sloan Kettering Gene Editing and Screening Core (Dow et al., 2012, Nature Prot. 2:374). In contrast to the TRC equivalents, none of these 6 viruses affected cell growth of HeyA8 cells in a major way (new [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). The conclusion that the expression of these shRNAs was too low to be toxic was based on our findings that expression of these shRNAs did not even result in a major silencing of the respective venus sensors (linked to either CD95 or the CD95L mRNA) (new [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). In contrast, the toxic shRNAs shL3 and shR6 expressed from our inducible vector pTIP shut down Venus expression completely (see [Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"}).

There certainly could be other reasons for the lack in shRNA activity from these vectors outside our control. We have revised the section in the Discussion. In general, we are not concerned about the discrepancy between our data and other screens using miR-30-based shRNAs given that not only shRNAs but also siRNAs, DsiRNAs, and shRNA-based siRNAs are all effective DISE inducers. Thus, the DISE inducing activity seems to be independent of the delivery vehicle.

In response to the second part of the reviewers' comment, we did titer siL3 to very low concentrations and the DISE inducing activity is indeed dose dependent (see new [Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}). siL3 transfected at 0.1 nM was no longer toxic. In another manuscript in preparation we determined the IC50 for siL3 to kill cells to be 0.8 nM (Murmann et al. in preparation).

> 4\) The authors produced 3 different target deletions (ΔsiL3, ΔshL3 and ΔshR6) in 293T or HeyA8 cells to show that expression of the si or shRNAs, even in the absence of the target, is still lethal. The deletions seem to produce frame-shift mutations in the coding sequence (as the nt deleted are not a multiple of 3). The authors indeed show that ΔshR6 produces a protein knockout, which they use for a different experiment (Figure 1---figure supplement 3). This provokes the question of whether this is also the case for ΔsiL3 and ΔshL3 and whether it is appropriate to call them \"target site\" mutants if they are indeed functional knockouts. The authors state in their Introduction \"after deleting the CD95 gene tumors barely grew in vivo (Chen et al., 2010; Hadji et al., 2014)\" so maybe they could comment on the fact that HeyA8 ΔshR6, being a functional knockout and not exclusively a target site mutant grows similar to the parental cell line ([Figure 1H](#fig1){ref-type="fig"}).

All deletions were purposely designed to both delete the targeted site and to produce frame-shift mutations. In the chosen cell lines, CD95L protein and mRNA are virtually undetectable to begin with. So demonstrating functional knock-outs is only feasible for the deletion of CD95. Because the goal was to eliminate the target sites of our si/shRNAs (which we accomplished), whether the cells are true functional knock-outs (meaning, no functional protein being produced) was secondary to the question that needed to be addressed. Having functional knock-outs was an added benefit.

The reviewers are correct. Based on our in vivo mouse model data we expected cancer cell lines to not grow well after deletion of CD95. When generating the single cell clones with the target site deletion (or the complete deletion of CD95, now in future manuscript) we consistently observed that cells indeed initially grew slower than wt cells but because the effect was reduced with prolonged culture and because this effect could have been caused by clonal differences, we decided to not include this observation in the manuscript. This requires further work.

Overall, we believe we are looking at two different phenomena. Firstly, sequences derived from CD95L for instance are toxic to cancer cells regardless of the expression of the target. Secondly, as pointed out by the reviewers, we have shown in different genetically engineered mouse tumor models that the CD95 gene/protein is required for cancer cells to form tumors in vivo. We and others have shown that CD95 is involved in the maintenance of cancer stem cells (Ceppi et al., 2014, Nature Com. 5:5238; Drachsler et al., 2016, Cell Death Dis, 7:e2209; Teodoczyk et al., 2015, Cell Death Differ, 22:1192). We recently demonstrated that this occurs by activating a type I interferon/STAT1 pathway (Qadir et al., 2017, Cell Rep, 10:2373). In addition, CD95L does promote cell growth. This is apparent from the experiment in which we added either soluble CD95L (S2) (new [Figure 1A](#fig1){ref-type="fig"}, left panel) or highly active leucine zipper tagged CD95L to the cells (new [Figure 1A](#fig1){ref-type="fig"}, center panel). In both cases, there was a small but reproducible and dose dependent increase in growth. We are currently testing whether these activities of CD95 are required for cancer cells to grow in syngeneic immune competent mouse models, which would explain the previous observations in the genetically engineered mouse tumor models.

> 5\) In [Figure 6](#fig6){ref-type="fig"} enforced expression of the CD95L mRNA is toxic in HeyA8 cells. However, in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, the CD95L-WT ORF is expressed (together with a scramble shRNA) and there is no observable increase in% subG1 compared to expression of vector only (together with a scramble shRNA) in either NB7 cells (panel D) or MCF-7 (panel G). Could the authors please comment on whether there are any other variables we should take into account or whether this is a cell type-specific phenotype. It is difficult to understand that NB7 lack caspase-8 but if they show the toxicity phenotype upon expression of the si/shRNAs and if over-expression of the CD95L is mediating the same phenotype, the model would predict CD95L would still cause lethality of this cell line.

The reviewers are correct. These data seem to contradict our finding on the toxicity of the CD95L ORF. DISE kills all cancer cells and caspase-8 deficiency has no effect on this form of cell death. The reason that the cells did not seem to die in this rescue experiment is the way it was performed. In the experiments shown in former [Figure 7](#fig7){ref-type="fig"} acute effects of CD95L ORF were monitored. Two days after infection with CD95L lentivirus, infected cells were selected for by treatment. After 24 hours in puromycin, cells were immediately plated for experiments. In contrast, in the experiment shown in [Figure 1D](#fig1){ref-type="fig"}, NB7 cells were infected with the CD95L lentivirus, selected for two days with puromycin and then cultured in the presence of puromycin for another 7 days. We made two observations: First, NB7 cells seem to be less susceptible to the cell death induced by CD95L ORF and second, after 9 days in culture enough cells had recovered and expressed the siRNA resistant protein to perform the experiment. Interestingly, these CD95L expressing cells were still sensitive to DISE induction by either shL1 or shL3. We have added a sentence to the manuscript to properly describe this observation. The data on expressing CD95 in MCF-7 cells formerly in [Figure 1---figure supplement 2G](#fig1s2){ref-type="fig"} are not affected by this discussion as CD95 expression was not found to be toxic to any cells.

> 6\) The authors perform a pooled screen to identify the most toxic sequences in the CD95 and CD95L genes ([Figure 5](#fig5){ref-type="fig"}). The pool screen analysis is performed comparing the final time points to the plasmid pool. This is concerning as virus production and infection could also lead to biases in the shRNA representation. As it stands, it could very well be that many of the \"depleted\" shRNAs were never present in the cells to begin with. This leads to particular concern about the results in the absence of doxycycline. The authors state that the depletion observed without adding dox is most likely due to leakiness in the Tet-on system (subsection "Identification of toxic shRNAs in the CD95L and CD95 mRNAs", second paragraph). However, in their initial experiments ([Figure 1G](#fig1){ref-type="fig"}) they expressed the highly toxic shRNA shL3 in 293T without any evidence of toxicity for at least 4 days. Thus, it would be very important to show the depletions observed in this pooled screen are indeed biological. Since the authors do not seem to have an initial post-infection time point to compare to, they could produce virus following the same set up and show that plasmid representation roughly corresponds to the shRNAs cloned from cells right after infection.

We discussed the design of this experiment in length during the planning of the shRNA screen and did many pilot experiments. First of all, the leakiness is not observed in all cells and not for all shRNAs, for reasons that are unclear. We found most effects of leakiness of the Tet inducible vector in HeyA8 and NB7 cells. 293T cells tolerate the vector expressing shL3 quite well and in these cells we do not see any effect on growth by just infecting them with the pTIP-shL3 vector in the absence of Dox, as seen in new [Figure 2G](#fig2){ref-type="fig"}. This cell specific sensitivity to vector leakiness is the reason we documented the leakiness in NB7 cells ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}) as this was most relevant to the actual screen which was performed in NB7 cells. As information for the reviewers, we chose NB7 cells for the screen because we had established the CD95L ORF venus sensor in this cell line, which allowed us to confirm shRNA knockdown activity (see [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). We found the CD95L Venus sensor vector to express very small amounts of active CD95L killing CD95 apoptosis sensitive cells. To avoid any interference by this activity, we chose the caspase-8 deficient NB7 cells for the screen.

We agree with the reviewers that it would have been preferable to have a true infection control. However, due to the high variance in toxicity caused by different degrees of leakage by different shRNAs we realized that such a control was not possible. Certain shRNAs would have already been underrepresented 48 hours after infection (the time we determined that was required in NB7 cells to complete infection and virus integration). We therefore decided to compare the three conditions: 1. Plasmid pool (as a control of sequence representation in the library). 2. Cells 12 days after infection and no Dox addition (this served as the infection control the reviewers asked for, however only for shRNAs that do not show leakiness) and 3. Cells 12 days after infection in the presence of Dox (this would reveal the underrepresented/toxic shRNAs that were highly induced by Dox, both for shRNAs with and without leakiness). So, while we share the concern raised by the reviewers, we would like to point out that the data plus Dox further depleted many shRNAs when compared to the cells minus Dox. Minus Dox in this case serves as an expression control. As a side remark, we noticed that in the comprehensive cell line analysis recommended to us by the reviewers above (Cowley et al., Sci. Data, 2014) the authors also did not include an expression control but -- similar to what we did -- they compared the abundance of the shRNAs to the initial plasmid pool. We assume this was done for the same reason, that one cannot be certain that even at early times after infection highly active shRNAs already are not being selected against. A true infection control is therefore not possible.

The individual expression levels of the shRNAs are given in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. While a very small number of shRNAs were not well expressed, the vast majority were and comparing the plus Dox with the minus Dox data we do have a relative presentation of each shRNA that takes into account infectious yield of many shRNAs. Importantly, underrepresented shRNAs identified in the comparison between library and no Dox treatment and between minus and plus Dox treatment mapped to similar regions in both CD95 and CD95L (compare [Figure 6D](#fig6){ref-type="fig"} blue with orange ticks) suggesting that the depletion is biological.

> 7\) Regarding the analysis of AGO-bound small RNAs that align to the CD95L, does the analysis take into account the possibility of PCR duplicates? Also, strand information is essential if the model is that this CD95L derived small RNAs are mediating knockdown of survival genes. The analysis text does not specify whether BLAST was run with any strand specificity so it would be essential for the authors to clarify.

We have moved this analysis to a manuscript to be published in the future. However, we would still like to answer the questions raised by the reviewers as we take them seriously. In addition, this will also explain why we felt that all these new data would be outside the focus recommended to us by the reviewers, and they would have further increased the size of this manuscript.

While PCR duplicates are always a concern, during the analysis we made sure that the PCR amplification was in the exponential phase. We actually performed extensive pilot PCRs. When done properly, PCR duplicates are of little concern and the biases in the library are stemming mainly from the 3' and 5' adapter ligation steps. Unfortunately, those cannot really be avoided entirely. We have previously published a careful study on biases in small RNA library preparations (Hafner et al., 2011, RNA, 17:1697).

The analysis was done in a strand specific fashion. All reads aligned are derived from the plus strand. Very few antisense reads were detected. We are aware that this raises the question of how these sequences can target survival genes through RNAi. We have generated new data to be published soon. These new data provide the first hint on how this might work. In the original manuscript, we showed in the highly DISE sensitive Drosha k.o. cells many more of the CD95L-derived reads are bound to AGO proteins when compared to wt cells. We have now performed an analysis of the total small RNAs in Drosha k.o. cells before they bind to AGO proteins. Overall, we find reads aligned to roughly to the same 22 regions in CD95L. However, overall reads in the cytosol tend to be longer than the ones bound to AGOs. In addition, we now have data on an RNA secondary structure prediction analysis for the CD95L ORF. According to this analysis the CD95L ORF RNA forms a tightly folded structure with many of the reads in the 22 regions juxtaposing each other in stem-like structures creating regions of significant complementarity. These may provide the duplexes needed to be processed and loaded into the RISC but this requires further work. We do not know yet what mRNA degrading system generated the small RNAs that are bound by AGO proteins. However, we see similar read locations when analyzing small CD95L derived RNAs in HeyA8 cells, both from total RNA as well as AGO bound (unpublished data) which could point at a general degradation mechanism. These new data will be part of the new manuscript we are now finalizing.

[^1]: These authors contributed equally to this work.
